Biosensor system for the rapid detection of analytes

ABSTRACT

A system, device, and method for rapid detection of analytes that includes a living, engineered biosensor cell that is typically a component of the mammalian immune system; a reporter protein that is engineered into and expressed by the living, engineered biosensor cell, wherein the reporter protein emits a detectable signal in response to certain predetermined changes in the cytosol of the living, engineered cell; a signal transduction pathway expressed by the living, engineered biosensor cell, wherein the signal transduction pathway controls a biological process within the cytosol of the living, engineered biosensor cell, and wherein the biochemical process, when it occurs, causes the reporter protein to emit a detectable signal; at least one type of detector molecule that is adapted to bind to a specific analyte; at least one analyte that binds to the detector molecule that is specific to that analyte; a plurality of non-antibody signal transducing elements that are either expressed by the living, engineered biosensor cell or that actively bind to a receptor or a receptor component expressed by the living, engineered biosensor cell, wherein each signal transducing element is adapted to receive a detector molecule.

CROSS-REFERENCE TO RELATED APPLICATIONS

This patent application claims the benefit of U.S. Provisional PatentApplication Ser. No. 62/140,920 filed on Mar. 31, 2015 and entitled“System for Rapid Detection of Analytes”, and U.S. Provisional PatentApplication Ser. No. 62/245,595 filed on Oct. 23, 2015 and entitled“Systems and Devices for the Rapid Detection of Analytes”, thedisclosures of which are incorporated by reference herein in theirentirety and made part of the present U.S. utility patent applicationfor all purposes.

BACKGROUND OF THE INVENTION

The described invention relates in general to systems, devices, andmethods for detecting various analytes in biological samples or othersample types, and more specifically to a biosensor-based system fordetecting and identifying analytes of interest in real time based on theemission of a detectable signal when the biosensor reacts with ananalyte of interest in a sample being tested.

In generic terms, a biosensor is a system or device for the detection ofan analyte that combines a sensitive biological component with aphysicochemical detector component. The components of a typicalbiosensor system include a biological element, a transducer or detectorelement, and associated electronics or signal processors that displaytest results in a meaningful and useful manner. The biological elementtypically includes biological material such as tissue, microorganisms,organelles, cell receptors, enzymes, antibodies, nucleic acids, and thelike that may be created by known biological engineering processes. Thetransducer or detector element works in a physicochemical manner (e.g.,optical, piezoelectric, and/or electrochemical) that transforms thesignal resulting from the interaction of the analyte with the biologicalelement into another signal that can be more easily measured andquantified. Biosensors originated from the integration of molecularbiology and information technology (e.g., microcircuits, optical fibers,etc.) to qualify or quantify biomolecule-analyte interactions such asantibody-antigen interactions. Considering that there is great demandfor rapid, sensitive, easy-to-handle, and cost-effective detection toolsfor detecting infectious agents, pathogens or/and toxins in food (see,for example, Mead et al., Food Related Illness and Death in the UnitedStates, Emerging Infectious Diseases; Vol. 5, No. 5, September-October1999 (607-625), which is incorporated by reference herein, in itsentirety), there is an ongoing need for the utilization of biosensors inreal-time, field-portable devices and instruments for the detection andidentification of infectious agents, pathogenic microorganisms, toxins,and other contaminants in foods and many other items.

SUMMARY OF THE INVENTION

The following provides a summary of certain exemplary embodiments of thepresent invention. This summary is not an extensive overview and is notintended to identify key or critical aspects or elements of the presentinvention or to delineate its scope.

In accordance with one aspect of the present invention, a first systemfor the rapid detection of analytes is provided. An exemplary embodimentof this first system includes a living, engineered biosensor cell thatis derived from a cellular component of the mammalian immune system; areporter protein that is engineered into and produced by the living,engineered biosensor cell and that emits a detectable signal in responseto certain predetermined changes in the cytosol of the living,engineered biosensor cell; a signal transduction pathway engineered intoor occurring naturally within the living, engineered biosensor cell thatcontrols a biological process within the cytosol of the living,engineered biosensor cell, wherein the biological process, when itoccurs, causes the reporter protein to emit a detectable signal; atleast one type of detector molecule, wherein each detector molecule isadapted to bind to a specific analyte; at least one analyte that bindsto the detector molecule and that is specific to that analyte; aplurality of transmembrane, non-antibody signal transducing elementsexpressed by the living, engineered biosensor cell, wherein each signaltransducing element is adapted to receive a detector molecule; andwherein upon the binding of a sufficient number of analytes to asufficient number of detector molecules that are themselves bound totransmembrane non-antibody signal transducing elements, an aggregationof signal transducing elements occurs on the biosensor cell surface, thesignal transduction pathway is activated, the biological process occurs,and the detectable signal is emitted by the reporter protein.

In accordance with another aspect of the present invention, a secondsystem for the rapid detection of analytes is provided. An exemplaryembodiment of this second system includes a living, engineered biosensorcell, wherein the living, engineered biosensor cell is derived from acellular component of the mammalian immune system, and wherein theliving, engineered biosensor cell expresses a plurality of at least onepredetermined type of receptor molecule on the surface thereof; areporter protein, wherein the reporter protein is engineered into andexpressed by the living, engineered biosensor cell, and wherein thereporter protein emits a detectable signal in response to certainpredetermined changes in the cytosol of the living, engineered cell; asignal transduction pathway engineered into or occurring naturallywithin the living, engineered biosensor cell, wherein the signaltransduction pathway controls a biological process within the cytosol ofthe living, engineered biosensor cell, and wherein the biologicalprocess, when it occurs, causes the reporter protein to emit adetectable signal; at least one type of detector molecule, wherein eachdetector molecule is adapted to bind to a specific analyte; at least oneanalyte, wherein the at least one analyte binds to the detector moleculethat is specific to that analyte; a plurality of soluble non-antibodysignal transducing elements, wherein each soluble signal transducingelement is adapted to bind to a receptor molecule and to a detectormolecule; and wherein upon the binding of a sufficient number ofanalytes to a sufficient number of detector molecules to a sufficientnumber of non-antibody signal transducing elements that are themselvesbound to the cell surface receptor molecules, an aggregation of thereceptor molecules occurs, the signal transduction pathway is activated,the biological process occurs, and the detectable signal is emitted bythe reporter protein.

In accordance with still another aspect of the present invention, abiosensor for the rapid detection of analytes in a sample is provided.This biosensor includes a living, engineered cell, wherein the living,engineered cell is derived from a cellular component of the mammalianimmune system (i.e., an immunocyte); a reporter protein, wherein thereporter protein is engineered into and expressed by the living,engineered cell, and wherein the reporter protein emits a detectablesignal in response to certain predetermined changes in the cytosol ofthe living, engineered cell; a signal transduction pathway engineeredinto or occurring naturally within the living, engineered cell, whereinthe signal transduction pathway controls a biological process within thecytosol of the living, engineered biosensor cell, and wherein thebiological process, when it occurs, causes the reporter protein to emita detectable signal; and a plurality of non-antibody signal transducingelements that directly or indirectly bind to an analyte in a sample tobe analyzed, wherein the bound non-antibody signal transducing elementsthen cooperate with the biosensor cell to directly or indirectlyactivate the signal transduction pathway.

Additional features and aspects of the present invention will becomeapparent to those of ordinary skill in the art upon reading andunderstanding the following detailed description of the exemplaryembodiments. As will be appreciated by the skilled artisan, furtherembodiments of the invention are possible without departing from thescope and spirit of the invention. Accordingly, the drawings andassociated descriptions are to be regarded as illustrative and notrestrictive in nature.

BRIEF DESCRIPTION OF THE DRAWINGS

The accompanying drawings, which are incorporated into and form a partof the specification, schematically illustrate one or more exemplaryembodiments of the invention and, together with the general descriptiongiven above and detailed description given below, serve to explain theprinciples of the invention, and wherein:

FIGS. 1a-b are illustrations of a first biosensor in accordance with anexemplary embodiment of the present invention, wherein Jurkat T cellshave been engineered to produce aequorin and to express thetransmembrane non-antibody signal transducing element IgGbp-CD3ζ;

FIGS. 2a-b are illustrations of a second biosensor in accordance with anexemplary embodiment of the present invention, wherein MC/9 mast cellshave been engineered to produce aequorin, and wherein the MC/9 cellsexpress the native receptor FcεRI, which binds to the solublenon-antibody signal transducing element IgGbp-IgE;

FIGS. 3a-b are illustrations of a third biosensor in accordance with anexemplary embodiment of the present invention, wherein MC/9 mast cellshave been engineered to produce aequorin, and wherein the MC/9 cellsexpress the native receptor FcεRI, which binds to the solublenon-antibody signal transducing element IgGbp-IgE, which has beenexcreted by the MC/9 mast cells;

FIG. 4 is an illustration of a fourth biosensor in accordance with anexemplary embodiment of the present invention, wherein biosensor cellshave been engineered to produce aequorin and to express thetransmembrane non-antibody signal transducing element mSA-CD3ζ, whichbinds to a biotinylated detector element; and

FIG. 5 is an illustration of a fifth biosensor in accordance with anexemplary embodiment of the present invention, wherein biosensor cellshave been engineered to produce aequorin and to express thetransmembrane non-antibody signal transducing element mSA-CD3ζ, whichbinds to a biotinylated detector element.

DETAILED DESCRIPTION OF THE INVENTION

Exemplary embodiments of the present invention are now described withreference to the Figures. Although the following detailed descriptioncontains many specifics for purposes of illustration, a person ofordinary skill in the art will appreciate that many variations andalterations to the following details are within the scope of theinvention. Accordingly, the following embodiments of the invention areset forth without any loss of generality to, and without imposinglimitations upon, the claimed invention.

The present invention relates in general to systems, devices, andmethods for detecting various analytes in biological samples or othersample types, and more specifically to a biosensor-based system fordetecting and identifying analytes of interest in real time based on theemission of a detectable signal when the biosensor reacts with ananalyte of interest in a sample being tested. The engineered cells ofthe present invention are extremely sensitive and effective biosensorsand because these biosensor cells have an intrinsic detection capacity,they provide a versatile system that can be readily adapted to detect awide variety of different infectious agents or other targets by simplyselecting alternative soluble detector (e.g., antibody) molecules withspecificity for a particular pathogen or other target of interest.Furthermore, the system of this invention can be readily configured formultiplex detection of several infectious agents or other analytes in asingle assay, providing for great flexibility and utility. Theversatility of the present invention is derived from a uniquecombination of elements and in particular from the combination of auniversal biosensor cell with a specific soluble detector (e.g.,antibody). The universal biosensor cell has the capacity to respond tothe presence of essentially any target molecule that can be recognizedby the detector molecule. Because, in some embodiments, the detector ordetector antibody is added to the system as a soluble factor, the systemmay be configured to detect an alternative target by simply selecting anappropriate alternate detector or detector antibody. The specificity ofthe disclosed system is determined by the detector molecule, which isselected based on its specificity and affinity for a target moleculethat is characteristic of an infectious agent or other target analyte.The combination of this universal biosensor cell and soluble detectoralso enables the construction of multiplex assays by simply including aplurality of detector molecules (e.g., antibodies) within the testsystem, wherein the target molecules are selected based on theirspecificity for alternative infectious agents or other analytes.

Genetic manipulation and modification of the biosensor cell types usedwith this invention typically involve the use of appropriately selectedgene delivery vehicles that contain genetic elements that functionefficiently in the cell type of choice. For example, it is useful toemploy a promoter element that directs high level expression ofintroduced transgenes in the specific biosensor cell of choice. In anexemplary embodiment of this invention, such a promoter element may bederived directly from the biosensor cell itself and then used to expressa transgene of interest. In another embodiment of this invention, anappropriate element may be determined empirically by comparing thefunction of alternative promoter elements in the context of alternativegene delivery vehicles in order to identify effective promoter,transgene, vector combinations for the cell type of choice. Transgenessuch as the gene encoding a luminescent reporter protein may beintroduced into the biosensor cell using standard techniques such aselectroporation or chemical transfection reagents such as, for example,lipofectamine. Other genetic engineering methods known to those ofordinary skill in the art are also compatible with the presentinvention.

In a generic embodiment, the present invention provides a system andmethod for rapid detection of analytes that includes the followingcomponents: (i) a living, engineered biosensor cell, wherein the livingengineered biosensor cell is a component of the mammalian immune system;(ii) a reporter protein, wherein the reporter protein is expressed bythe living, engineered biosensor cell, and wherein the reporter proteinemits a detectable signal in response to certain predetermined changesin the cytosol of the living, engineered cell; (iii) a signaltransduction pathway expressed by the living, engineered biosensor cell,wherein the signal transduction pathway controls a biological orbiochemical process within the cytosol of the living, engineeredbiosensor cell, and wherein the biological or biochemical process, whenit occurs, causes the reporter protein to emit a detectable signal; (iv)at least one type of detector molecule, wherein each detector moleculeis adapted to bind to a specific analyte; (v) at least one analyte,wherein the at least one analyte binds to the detector molecule that isspecific to that analyte; (vi) a plurality of non-antibody signaltransducing elements that are either expressed by the living, engineeredbiosensor cell or that actively bind to a receptor or a receptorcomponent expressed by the living, engineered biosensor cell, whereineach signal transducing element is adapted to receive a detectormolecule. Upon the binding of a sufficient number of analytes to asufficient number of detector molecules that are themselves bound to thenon-antibody signal transducing elements, an aggregation of signaltransducing elements occurs on the cell surface, the signal transductionpathway is activated, the biochemical process occurs, and the detectablesignal is emitted by the reporter protein. This system may also includea device for mixing the living cells together with soluble componentsand a sample containing an analyte or infectious agent of interest whilemaintaining the viability and functionality of the living biosensorcell, and a detector for detecting the signal emitted by the biosensorcell.

Living, Engineered Biosensor Cell

Exemplary embodiments of this invention include a living, engineeredbiosensor cell that is typically a component of the mammalian immunesystem, e.g., an immunocyte. In certain embodiments of this invention,the biosensor cell is a human or mouse B cell. B cells or B lymphocytes,are a type of white blood cell of the lymphocyte subtype that functionin the humoral immunity component of the adaptive immune system bysecreting antibodies. In other embodiments of this invention, thebiosensor cell is a human or mouse T cell. T cells or T lymphocytes areanother type of lymphocyte that play a central role in cell-mediatedimmunity as part of the adaptive immune system. T cells aredistinguishable from other lymphocytes due to the presence of a T-cellreceptor on the cell surface. In other embodiments of this invention,the biosensor cell is a mast cell. A mast cell is also a type of whiteblood cell known as a granulocyte that is derived from the myeloid stemcell that is a part of the immune and neuroimmune systems. Other typesof cells are compatible with this invention, including basophils, whichare another type of white blood cell, and which are similar in bothappearance and function to mast cells.

Reporter Protein

Exemplary embodiments of this invention include a reporter element, suchas a reporter protein or enzyme that is produced or expressed by theliving, engineered biosensor cell. The reporter protein emits adetectable signal in response to certain predetermined changes in thecytosol of the living, engineered biosensor cell. In certain embodimentsof this invention, the reporter protein is a bioluminescent photoproteinsuch as aequorin, which is derived from the hydrozoan Aequorea Victoria.Aequorin has been previously used for engineering living biosensor cellsto produce light signals in response to activation of a wide variety ofsignal transduction pathways; thus, various methods for manipulating theproduction of aequorin in living cells are well known to the skilledartisan. In particular, a skilled artisan may selected and employ anyappropriate gene delivery vehicle such as, for example, bacterialplasmid vectors or viral vectors, for introducing the appropriategenetic material into the biosensor cells. Production of the reporterprotein within the biosensor cell will then be controlled by expressionof the introduced genetic material. One having ordinary skill in the artwill also appreciate that other photoproteins or other types of reporterproteins, enzymes, and molecules may be incorporated into and utilizedwith various alternate embodiments of the present invention.

Signal Transduction Pathway

Exemplary embodiments of this invention include a signal transductionpathway expressed by the living, engineered biosensor cell. The signaltransduction pathway controls at least one biological process within thecytosol of the living, engineered cell, and the at least one biologicalprocess, when it occurs, causes the reporter protein to emit adetectable signal. In certain embodiments of this invention, the signaltransduction pathway is any biochemical pathway in which an increase inintracellular Ca2+ concentration is induced in response to activation ofa cell surface signal transducing molecule, such as a receptor protein.The biosensor cells used with this invention may be selected from a setof living cells that are capable of producing an increase in cytoplasmicCa2+ in response to activation of a cell surface signal transductionmolecule. For example, B cells, T cells, and mast cells have thecapacity to induce an increase in Ca2+ concentration in response toactivation of cell surface signal transducing molecules such as the Bcell receptor, the T cell receptor, and the Fc epsilon receptor (mastcells), respectively.

Because mammalian cells growing in culture typically generatepopulations of cells in which specific individual cells may havediffering capacities to induce an increase in Ca2+ concentration, it isuseful to select for or screen for subpopulations of cells or clonalcell lines that have a robust ability to generate the Ca2+ signal. Thismay be accomplished by analyzing induction of an aequorin induced flash,for example. In particular, the transfectants created by theintroduction of transgenes into a cell are a mixed population of cellsderived from a large number of independent gene insertion events. Thus,when constructing a biosensor cell it is useful to screen or selectspecific subsets of cells or clonal cell lines that have efficientsignal transduction capabilities together with useful levels ofexpression of introduced transgenes. It is particularly useful to usefluorescence-activated cell sorting (FACS) technology to select forsubpopulations of high expressing cells or to generate clonal cell linesfor this purpose.

As previously stated, aequorin has been used previously for engineeringliving biosensor cells to produce light signals in response toactivation of a wide variety of signal transduction pathways,particularly wherein such signal transduction pathways lead to anincrease in cytoplasmic Ca2+ ions within a living cell. In certainembodiments of this invention, biosensor cells that produce aequorin asthe reporter protein are charged with coelenterazine (CTZ) prior totheir use in a detection assay. This charging step covalently links theaequorin to a hydrophobic prosthetic group (e.g., CTZ) and upon calcium(Ca2+) binding, the CTZ undergoes an irreversible reaction that includesa conformation change, and emits blue light (at 469 nm).

Detector Molecule

Exemplary embodiments of this invention include at least one type ofdetector element such as a detector molecule, wherein each detectormolecule is adapted to bind to a specific target analyte. The detectormolecule may a soluble antibody that is not in any way expressed by thebiosensor cells. The particular detector molecule used with the presentinvention is selected based on its ability to unambiguously identify thetarget analyte of interest. In an exemplary embodiment, the detectormolecule is a soluble antibody such as a commercially available IgG thatis specific for a particular analyte, such as an infectious agent. Inanother exemplary embodiment, the detector molecule is a biotinylatedmolecule (or streptavidin-based molecule) that is specific for apredetermined analyte such as, for example, a biotinylated autoantigenmolecule that is specific for an anti-autoantigen antibody. A detectoror target molecule according to this invention may include anautoantigen or an autoantibody associated with an autoimmune disease.Representative autoimmune diseases or disorders include rheumatoidarthritis (RA), juvenile RA (JRA), diabetes mellitus type 1, systemiclupus erythematosus, Hashimoto's thyroiditis, Graves' disease,scleroderma, celiac disease, Crohn's disease, ulcerative colitis,Sjogren's syndrome, multiple sclerosis, Goodpasture's syndrome,Addison's disease, Wegener's granulomatosis, primary biliary cirrhosis,sclerosing cholangitis, autoimmune hepatitis, polymyalgia rheumatica,temporal arteritis/giant cell arteritis, and Guillain-Barre syndrome.Detector or target molecules may also comprise tumor-specific ortumor-associated antigens or antibodies to such antigens; orbiologically active molecules, such as EGF, peptide hormones, includinginsulin and growth hormone, cytokines, interleukins, interferons, TNF,etc. or antibodies to such biologically active molecules.

Analyte and Test Sample

An intended use of the present invention is the detection of variousanalytes that are or might be present within samples to be tested. In anexemplary embodiment of this invention, an analyte that is to bedetected will bind to a detector molecule, such as a soluble antibody,that is specific to that analyte. A sample to be tested may be takenfrom a large number of food sources, including: (i) meats such as beef,pork, lamb, bison, poultry, and seafood; and (ii) plants and vegetables.A sample to be tested may also be taken from many other sources such aswater, consumable fluids, preservative fluids, and bodily fluids such asblood. Analytes that may be detected include virtually anything thatwill bind with specificity to the detector or detector molecule such aschemicals, toxins, and infectious agents such as viruses, bacteria, andother biological materials or agents. In an exemplary embodiment of thisinvention, the specific infectious agent is Escherichia coli, althoughother infectious agents (such as Salmonella, Listeria, andCampylobacter) and contaminants may be detected with the presentinvention. Escherichia coli O157 H7, O26, O45, O103, O111, O121, andO145, in either separate assays or multiplexed assays, may allpotentially be detected using this invention.

The present invention is capable of detecting many different analytesincluding meat pathogens, and those found on spinach, lettuce, and othervegetables and foods. An analyte may contain one or more epitopes of anantigen or allergen, including both linear or conformation epitopes; itmay also contain one or more ligands or receptors recognized byreciprocal receptors or ligands. Exemplary analytes include a bacterium,such as Bacillus (e.g., B. anthracis), Enterobacteriaceae (e.g.,Salmonella, Escherichia coli, Yersinia pestis, Klebsiella, andShigella), Yersinia (e.g., Y. pestis or Y. enterocolitica),Staphylococcus (e.g., S. aureus), Streptococcus, Gonorrheae,Enterococcus (e.g., E. faecalis), Listeria (e.g., L. monocytogenes),Brucella (e.g., B. abortus, B. melitensis, or B. suis), Vibrio (e.g., V.cholerae), Corynebacterium diphtheria, Pseudomonas (e.g., P.pseudomallei or P. aeruginosa), Burkholderia (e.g., B. mallei or B.pseudomallei), Shigella (e.g., S. dysenteriae), Rickettsia (e.g., R.rickettsii, R. prowazekii, or R. typhi), Francisella tularensis,Chlamydia psittaci, Coxiella burnetii, Mycoplasma (e.g., M. mycoides),etc.; allergens, such as peanut dust, mycotoxins, mold spores, orbacterial spores such as Clostridium botulinum and C. perfringens;toxins, such as ricin, mycotoxin, tetrodotoxin, anthrax toxin, botulinumtoxin, staphylococcal entertoxin B, or saxitoxin; a virus, such asAdenoviridae (e.g., adenovirus), Arenaviridae (e.g., Machupo virus),Bunyaviridae (e.g., Hantavirus or Rift Valley fever virus),Coronaviridae, Orthomyxoviridae (e.g., influenza viruses), Filoviridae(e.g., Ebola virus and Marburg virus), Flaviviridae (e.g., Japaneseencephalitis virus and Yellow fever virus), Hepadnaviridae (e.g.,hepatitis B virus), Herpesviridae (e.g., herpes simplex viruses),Papovaviridae (e.g., papilloma viruses), Paramyxoviridae (e.g.,respiratory syncytial virus, measles virus, mumps virus, orparainfluenza virus), Parvoviridae, Picornaviridae (e.g., polioviruses),Poxviridae (e.g., variola viruses), Reoviridae (e.g., rotaviruses),Retroviridae (e.g., human T cell lymphotropic viruses (HTLV) and humanimmunodeficiency viruses (HIV)), Rhabdoviridae (e.g., rabies virus), andTogaviridae (e.g., encephalitis viruses, yellow fever virus, and rubellavirus)); a protozoon, such as Cryptosporidium parvum, Encephalitozoa,Plasmodium, Toxoplasma gondii, Acanthamoeba, Entamoeba histolytica,Giardia lamblia, Trichomonas vaginalis, Leishmania, or Trypanosoma(e.g., T. brucei and T. Cruzi); a helminth, such as cestodes(tapeworms), trematodes (flukes), or nematodes (roundworms, e.g.,Ascaris lumbricoides, Trichuris trichiura, Necator americanus, orAncylostoma duodenale); a parasite (e.g., any protozoa or helminthsdescribed herein); a fungus, such as Aspergilli, Candidae, Coccidioidesimmitis, and Cryptococci; an environmental contaminant; a wateradditive; an agricultural marker; a nucleic acid (e.g.,oligonucleotides, polynucleotides, nucleotides, nucleosides, moleculesof DNA, or molecules of RNA, including a chromosome, a plasmid, a viralgenome, a primer, or a gene); a protein (e.g., a glycoprotein, ametalloprotein, an enzyme, a prion, or an immunoglobulin); a metabolite;a sugar; a lipid; a lipopolysaccharide; a salt; or an ion. Targets alsoinclude food-borne pathogens, such as Salmonella (e.g., SalmonellaTyphimurium), pathogenic E. coli (e.g., O157:H7), Bacillus (e.g., B.cereus), Clostridium botulinum, Listeria monocytogenes, Yersinia (e.g.,Y. enterocolitica), Norovirus (e.g., Norwalk virus), Shigella.Staphylococcus aureus, Toxoplasma gondii, Vibrio (e.g., V. vulnificus,V. cholera, V. parahaemolyticus), Campylobacter jejuni, and Clostridiumperfringens; and weaponized pathogens, such as Bacillus anthracis,Yersinia pestis, Francisella tularensis, Brucella (e.g., B. suis),Burkholderia mallei, Burkholderia pseudomallei, Shigella, Clostridiumbotulinum, Variola (e.g., V. major), Filoviridae (e.g., Ebola virus andMarburg virus), Arenaviridae (e.g., Lassa virus and Machupo virus),Clostridium perfringens, any food-borne pathogen (e.g., Salmonellaspecies, Escherichia coli O157:H7, or Shigella), Chlamydia psittaci,Coxiella burnetii, Staphylococcal aureus, Rickettsia (e.g., R.prowazekii or R. rickettsii), Alphavirus (e.g., Venezuelan equineencephalitis virus, eastern equine encephalitis virus, or western equineencephalitis virus), Vibrio cholerae, Cryptosporidium parvum,Henipavirus (e.g., Nipah virus), Bunyaviridae (e.g., Hantavirus or RiftValley fever virus), Flaviviridae (e.g., Japanese encephalitis virus andYellow fever virus), and Coccidioides spp.

Epitopes that can be detected as analytes or portions of an analyte aretypically antigenic determinant sites on an antigen to which animmunogolublin (or antigen binding fragment thereof) can specificallybind. Epitopes can be formed both from contiguous amino acids ornoncontiguous amino acids juxtaposed by tertiary folding of a protein.Epitopes can be found on the Fab (variable) region of immunoglobulins(referred to as “idiotypic determinants”) and comprise theimmunoglobulin's “idiotype”. The epitope and antigen can be naturallyoccurring or artificially produced. Depending on the nature of theepitope or antigen, the epitope or antigen can be isolated or purifiedfrom a matrix or substance of origin, synthesized, or recombinantlyproduced, for example. Epitopes and antigens useful as analytes can befrom a human or non-human animal, plant, bacteria, protozoan, parasite,virus, etc. In some embodiments, the analyte is a polypeptide, nucleicacid molecule, carbohydrate, glycoprotein, lipid, lipoprotein,glycolipid, or small molecule. In some embodiments, the analyte isselected from among a cancer antigen, autoantigen, allergen, endogenousantigen, infectious agent antigen, drug (small molecule) antigen, toxin,venom, biologic antigen, environmental antigen, transplant antigen, andimplant antigen.

An analyte may comprise an epitope of a cancer antigen. In someembodiments, the analyte is a tumor-associated antigen. In someembodiments, the analyte is a tumor-specific antigen. In someembodiments of the invention, the analyte is a tumor-associated antigen(TAA), and the TAA is a carbohydrate antigen having one or morepost-translational modifications that differ from the wild-type protein,comprises a fusion region of a protein resulting from a gene fusion thatis present in malignant cells but not present in non-malignant cells,and/or wherein the TAA comprises a receptor tyrosine kinase (RTK) thatis deregulated and/or dysfunctional in tumor cells due to autocrineactivation, chromosomal translocations, RTK overexpression, orgain-of-function mutations in the RTK gene or protein. In someembodiments of the invention, the analyte is an immunoglobulin expressedby a B-cell malignancy. Examples of B-cell malignancies include, but arenot limited to, non-Hodgkin's lymphoma, Hodgkin's lymphoma, chroniclymphocytic leukemia, mantle cell lymphoma and multiple myeloma.Additional B-cell malignancies include, for example. B-cellprolymphocytic leukemia, lymphoplasmocytic leukemia, splenic marginalzone lymphoma, marginal zone lymphoma (extra-nodal and nodal), plasmacell neoplasms (e.g., plasma cell myeloma, plasmacytoma, monoclonalimmunoglobulin deposition diseases, heavy chain diseases), andfollicular lymphoma (e.g., Grades I, II, III, or IV).

In some embodiments, the analyte is a tumor-associated antigen derivedfrom tumor cells obtained from the subject. In some embodiments, thetumor-associated antigen is one or more antigens selected from among17-1A, 707-AP, AFP, Annexin II, ART-4, BAGE, BAGE-1, .beta.-catenin,BCG, bcr/abl, Bcr/abl e14a2 fusion junction, bcr-abl (b3a2), bcr-abl(b3a2), bcr-abl p190 (ela2), bcr-abl p210 (b2a2), bcr-abl p210 (b3a2),bcr-abl p210 (b3a2), bullous pemphigoid antigen-1, CA19-9, CA125, CA215,CAG-3, CAMEL, Cancer-testis antigen, Caspase-8, CCL3, CCL4, CD16, CD20,CD3, CD30, CD55, CD63, CDC27, CDK-4, CDR3. CEA, cluster 5, cluster-5A,cyclin-dependent kinase-4, Cyp-B, DAM-10, DAM-6, Dek-cain, E7, EGFR,EGFRvIII, EGP40, ELF2 M, EpCAM, FucGM1, G250, GA733, GAGE, GAGE-1-8,gastrin cancer associated antigen, GD2, GD3, globoH, glycophorin, GMI,GM2, GM3, GnTV, Gn-T-V, gp100, Her-2/neu, HERV-K-ME, high molecularweight-associated antigen, high molecular weight proteo-glycan (HMPG),HPV-16 E6, HPV-16 E7, HPVE6, HSP70-2M, HST-2, hTERT, human chorionicgonadotropin (HCG), Human milk fat globule (HMFG), iCE, KIAA0205,KK-LC-1, KM-HN-1, L6, LAGE-1, Lcose4Cer, LDLR/FUT, Lewis A. Lewis v/b, Mprotein, MAGE-1, MVC, MAGE-Al-12, MAGE-C2. MAHGE-3, MART-I/Melan-A,MCIR, Me.491, MUCI, MUC2, mucin, MUM-I, MUM-2, MUM-3, mutated p53,Myosin, MZ2-E, N9 neuraminidase, NA88, NA88-A, nasopharyngeal carcinomaantigen, NGA, NKI/c-3, Novel bcr/ablk fusion BCR exons 1, 13, 14 withABL exons 4, NY-ESO-1/LAGE-2, NY-ESO-1b, OC125, osteosarcoma associatedantigen-I, P15, p190 mimor bcr-abl (ela2), p53, Pm1/RARa, Polysialicacid, PRAME, PSA, PSM, RUI, RU2, SAGE, SART-1, SART-2, SART-3, SialylLeA, Sp17, SSX-2, SSX-4, surface immunoglobulin, TAG-i, TAG-2, TEL/AML1,TPI, TRAG-3, TRP-1 (gp75), TRP-2, TRP2-INT2, hTRT, tumor associatedglycoprotein-72 (TAG-72), tyrosinase, u-PA, WTI, and XAGE-1b, or animmunogenic fragment of any of the foregoing antigens. In someembodiments, the tumor associated antigen is identified by the SEREX(serological analysis of recombinant cDNA expression library) approachor based on the serological screening of cDNA expression librarygenerated from tumor tissues of various origin or cancer cell lines, andidentifying immunogenic tumor proteins based on their reactivity withautologous patient sera. In some embodiments, the analyte is atumor-associated antigen that is acarbohydrate antigen having one ormore post-translational modifications that differ from the wild-typeprotein. In some embodiments, the tumor-associated antigen comprises afusion region of a protein resulting from a gene fusion that is resentin malignant cells but not present in non-malignant cells. In someembodiments, the tumor-associated antigen comprises a receptor tyrosinekinase that is deregulated and/or dysfunctional in tumor cells due toautocrine activation, chromosomal translocations, RTK overexpression, orgain-of-function mutations in the RTK gene or protein.

The analyte may comprise an epitope of an antigen of an infectious ornoninfectious agent that can be either pathogenic or non-pathogenic tothe subject. The analyte can be derived from a mutualistic, parasitic,or commensal microorganism, including any microorganism in a animal orplant biome, such as probiotic or commensal microorganisms in the humandigestive tract, mucosal surfaces, or epithelium. In some embodiments,the bacterial pathogen is selected from among Acinetobacter baumannii(formerly Acinetobacter calcoaceticus), Actinobacillus, Actinomycespyogenes (formerly Corynebacterium pyogenes), Actinomyces israelii,nocardia asteroids, N. brasiliensis, Aeromonas hydrophila, Amycolataautotrophica, Archanobacterium haemolyticum (formerly Corynebacteriumhaemolyticum), Arizona hinshawii—all serotypes, Bacillus anthracis,Bacteroides fragilis, Bartonella henselae, B. quintana, B. vinsonii,Bordetella including B. pertussis, Borrelia recurrentis, B. burgdorferi,Burkholderia (formerly Pseudomonas species) except those listed in BSLIII), Campylobacter coli, C. fetus, C. jejuni, Chlamydia psittaci, C.trachomatis, C. pneumonia, Clostridium botulinum (neurotoxin producingspecies), Clostridium botulinum neurotoxins, Cl. chauvoei, Cl.haemolyticum, Cl. histolyticum, Cl. novyi, Cl. septicum, Cl. Tetani, Cl.Perfirngens epsilon toxin, Corynebacterium diphtheriae, C.pseudotuberculosis, C. renale, Dermatophilus congolensis, Edwardsiellatarda, Erysipelothrix rhusiopathiae, Escherichia coli—allenteropathogenic, enterotoxigenic, enteroinvasive and strains bearing KIantigen, including E. coli O157:H7, Haemophilus ducreyi, H. influenzae,Helicobacter pylori, Klebsiella—all species except K. oxytoca (RG1),Legionella including L. pneumophila, Leptospira interrogans-allserotypes, Listeria, Moraxella, Mycobacterium (except those listed inBSL III) including M. avium complex, M. asiaticum, M. bovis BCG vaccinestrain, M. chelonei, M. fortuitum, M. kansasii, M. leprae, M. malmoense,M. marinum, M. paratuberculosis, M. scrofulaceum, M. simiae, M. szulgai,M. ulcerans, M. xenopi, Mycoplasma, Neisseria gonorrhoeae, N.meningitides, Nocardia asteroides, N. brasiliensis, N. otitidiscaviarum,N. transvalensis, Proteus mirabilis, P. vulgaris, Rhodococcus equi,Salmonella including S. arizonae, S. cholerasuis, S. enteritidis, S.gallinarum-pullorum, S. meleagridis, S. paratyphi, A, B, C, S. typhi, S.typhimurium, Shigella including S. boydii, S. dysenteriae, type 1, S.flexneri, S. sonnei, Sphaerophorus necrophorus, Staphylococcus aureus,Streptobacillus moniliformis, Streptococcus including S. pneumoniae, S.pyogenes, Treponema pallidum, T. carateum, Vibrio cholerae, V.parahemolyticus, V. vulnificus, Yersinia enterocolitica, Bartonella,Brucella including B. abortus, B. canis, B. suis, B. melitensis,Burkholderia (Pseudomonas) mallei, B. pseudomallei, Coxiella burnetii,Francisella tularensis, Mycobacterium bovis (except BCG strain, BSLII—Bacterial Agents Including Chlamydia), M. tuberculosis, Mycobacteriaother than tuberculosis (MOTT), Pasteurella multocida type B—“buffalo”and other virulent strains. Rickettsia akari, R. australis, R. canada,R. conorii, R. prowazekii, R. rickettsii, R. siberica, R. tsutsugamushi,R. typhi (R. mooseri), Yersinia pestis.

The analyte can be derived from a viral pathogen. For example, in someembodiments, the analyte is derived from a viral pathogen selected fromamong Adenoviruses, human—all types, Alphaviruses (Togaviruses), Easternequine encephalitis virus, Eastern equine encephalomyelitis virus,Venezuelan equine encephalomyelitis vaccine strain TC-83, Western equineencephalomyelitis virus, Arenaviruses, Lymphocytic choriomeningitisvirus (non-neurotropic strains), Tacaribe virus complex, Bunyaviruses,Bunyamwera virus, Rift Valley fever virus vaccine strain MP-12,Calciviruses. Coronaviruses. Flaviviruses (Togaviruses)-Group BArboviruses, Dengue virus serotypes 1, 2, 3, and 4, Yellow fever virusvaccine strain 17D, Hepatitis A, B, C, D, and E viruses, theCytomegalovirus, Epstein Barr virus. Herpes simplex types 1 and 2,Herpes zoster, Human herpesvirus types 6 and 7, Influenza viruses typesA, B, and C, Papovaviruses, Papilloma viruses, Newcastle disease virus,Measles virus, Mumps virus, Parainfluenza viruses types 1, 2, 3, and 4,polyomaviruses (JC virus, BK virus), Respiratory syncytial virus, Humanparvovirus (B 19), Coxsackie viruses types A and B, Echoviruses,Polioviruses, Rhinoviruses, Alastrim (Variola minor virus), Smallpox(Variola major virus), Whitepox Reoviruses, Coltivirus, human Rotavirus,and Orbivirus (Colorado tick fever virus), Rabies virus, Vesicularstomatitis virus, Rubivirus (rubella), Semliki Forest virus, St. Louisencephalitis virus, Venezuelan equine encephalitis virus, Venezuelanequine encephalomyelitis virus, Arenaviruses (a.k.a. South AmericanHaemorrhagic Fever virus), Flexal, Lymphocytic choriomeningitis virus(LCM) (neurotropic strains), Hantaviruses including Hantaan virus, RiftValley fever virus, Japanese encephalitis virus, Yellow fever virus,Monkeypox virus, Human immunodeficiency virus (HIV) types 1 and 2, HumanT cell lymphotropic virus (HTLV) types 1 and 2, Simian immunodeficiencyvirus (SIV), Vesicular stomatitis virus, Guanarito virus, Lassa fevervirus, Junin virus, Machupo virus, Sabia, Crimean-Congo hemorrhagicfever virus, Ebola viruses, Marburg virus, Tick-borne encephalitis viruscomplex (flavi) including Central European tick-borne encephalitis, FarEastern tick-borne encephalitis, Hanzalova, Hypr, Kumlinge, KyasanurForest disease, Omsk hemorrhagic fever, and Russian Spring Summerencephalitis viruses, Herpesvirus simiae (Herpes B or Monkey B virus),Cercopithecine herpesvirus 1 (Herpes B virus), Equine morbillivirus(Hendra and Hendra-like viruses), Nipah virus, Variola major virus(Smallpox virus), Variola minor virus (Alastrim), African swine fevervirus, African horse sickness virus, Akabane virus, Avian influenzavirus (highly pathogenic), Blue tongue virus, Camel pox virus, Classicalswine fever virus, Cowdria ruminantium (heartwater), Foot and mouthdisease virus, Goat pox virus, Japanese encephalitis virus, Lumpy skindisease virus, Malignant catarrhal fever virus, Menangle virus,Newcastle disease virus (VVND), Peste Des Petits Ruminants virus,Rinderpest virus, Sheep pox virus, Swine vesicular disease virus,Vesicular stomatitis virus (exotic).

The analyte can be derived from a parasite. For example, in someembodiments, the analyte is derived from a parasite selected from amongAncylostoma human hookworms including A. duodenale, A. ceylanicum,Ascaris including Ascaris lumbricoides suum, Babesia including B.divergens, B. microti, Brugia filaria worms including B. malayi, B.timori, Coccidia, Cryptosporidium including C. parvum, Cysticercuscellulosae (hydatid cyst, larva of T. solium), Echinococcus including E.granulosis, E. multilocularis, E. vogeli, Entamoeba histolytica,Enterobius, Fasciola including F. gigantica, F. hepatica, Giardiaincluding G. lamblia, Heterophyes, Hymenolepis including H. diminuta, H.nana, Isospora, Leishmania including L. braziliensis, L. donovani, L.ethiopia, L. major, L. mexicana, L. peruvania, L. tropica, Loa loafilaria worms, Microsporidium, Naegleria fowleri, Necator humanhookworms including N. americanus, Onchocerca filaria worms including,O. volvulus, Plasmodium cynomologi, P. falciparum, P. malariae, P.ovale, P. vivax, Sarcocystis including S. sui hominis, Schistosomaincluding S. haematobium, S. intercalatum, S. japonicum, S. mansoni, S.mekongi, Strongyloides including S. stercoralis, Taenia solium, Toxocaraincluding T. canis, Toxoplasma including T. gondii, Trichinellaspiralis, Trypanosoma including T. brucei brucei, T. brucei gambiense,T. brucei rhodesiense, T. cruzi, or Wuchereria bancrofti filaria worms.

The analyte can be a fungal pathogen. For example, in some embodiments,the analyte is derived from a fungal pathogen selected from amongAspergillus fumigates, Blastomyces dermatitidis, Cladosporium bantianum,Candida albicans, C. (Xylohypha) trichoides, Cryptococcus neoformans,Dactylaria galopava (Ochroconis gallopavum), Epidermophyton, Exophiala(Wangiella) dermatitidis, Fonsecaea pedrosoi, Microsporum,Paracoccidioides braziliensis, Penicillium marneffei, Pneumocystiscarinii, Sporothrix schenckii, Trichophyton, Coccidioides immitis,Coccidioides posadasii, Histoplasma capsulatum, H. capsulatum var.duboisii.

The analyte can be a toxin. In some embodiments, the analyte is a toxinselected from among Abrin, Botulinum neurotoxins, Clostridiumperfringens epsilon toxin, Conotoxins, Diacetoxyscirpenol, Ricin,Saxitoxin, Shiga-like ribosome inactivating proteins, Shigatoxin,Staphylococcal enterotoxins, T-2 toxin, and tetrodotoxin.

In some embodiments, the analyte is selected from among Hepatitis Bsurface antigen (HBsAg), B. burgdorferi OspA, HPV L1, RSV F protein,Influenza hamagglutanin, Influenza stem-loop region, Influenza M2, P.falciparum merozoite surface protein 1-10, GLURP, SERA, S-antigen, 6-cysfamily, AMA1, EBA175, 140, 181, MTRAP, PTRAMP, ASP, Rh1, 2a, 2b, 4, 5,RAPI, 2, 3, RAMA, RHOPH1, 2, 3, P. vivax circumsporozoite protein,sporozoite surface proetin2, SSP2/TRAP, CSP-N, CSP-R, CSP-C, MSP-1,MSP-9, DBPRIII, AMA-1, Pvs25, Pvs28, S. aureus capsular polysaccharide,poly-N-acetyl glucosamine, HIV gp120, gp41, and Dengue virus conservedregions.

In another embodiment the analyte comprises at least one epitope of anallergen. Allergens can be naturally occurring, or artificial such asallergens contained in allergy vaccines. Examples of allergens include,but are not limited to, animal products (for example, Fel d 1, furdander, cockroach calyx, wool, dust mite excretion), drugs (for example,penicillin, sulfonamides, salicylates, local anaesthetic), food (forexample, celery and celeriac, corn, eggs (e.g., albumin), fruit, legumes(for example, beans, peas, peanuts, soybeans), milk, seafood (e.g.,shellfish), sesame, soy, tree nuts (for example, pecans, almonds),wheat, insect venom (for example, fire ants, bee sting venom, wasp stingvenom), latex, metal, plant pollen (for example, grass (e.g., ryegrass,timothy-grass, weeds (e.g., ragweed, plantago, nettle, Artemisiavulgaris, chenopodium album, sorrel), and trees (e.g., birch, alder,hazel, hornbeam, aesculus, willow, poplar, platanus, tilia, olea, Ashejuniper).

In some embodiments, the analyte is an allergen derived from a latexprotein, for example, unprocessed latex sap, raw latex containingammonia, or finished latex product in which the proteins have beenexposed to chemicals and high temperatures. In some embodiments, theallergen is the allergen of a mite, for example, Dermatophagoidesfarinae, Dermatophagoides pteronyssinus, Acarus siro, Blomia tropicalis,Chortoglyphus arcuatas, Euroglyphus cannei, Lepidoglyphus destructor,Tyrophagus putrescentiae, or Glyphagus demesticus. In some embodiments,the allergen is from venom, for example, Bombus spp., Vespa crabro, Apismellifera, Dolichovespula spp., Polistes spp., Vespula spp.,Dolichovespula maculata, or Dolichovespula arenaria. In someembodiments, the analyte is an allergen from an insect, for example,Camponotus pennsylvanicus, Solenopsis invicta, Solenopsis richteri,Periplaneta americana, Blattella germanica, Blatta orientails, Tebanusspp., Musca domestica, Ephemeroptera spp., Culicidae sp., or Heteroceraspp.

In some embodiments, the allergen analyte is epithelia, dander, or hairfrom an organism, for example, Serinus canaria, Felis catus(domesticus), Bos taurus, Gallus gallus (domesticus), Canis familiaris,Arias platyrhynchos, Meriones unguiculatus, Capra hircus, Anserdomesticus, Cavia porcellus (cobaya), Mesocrietus auratus, Sus scrofa,Equus caballus, Mus musculus, Psittacidae, Columba fasciata, Oryctolaguscuniculus, Rattus norvegicus, or Ovis aries.

In some embodiments, the allergen analyteis from fungi, for example,Cephalosporium acremonium, Alternaria tenuis, Aspergillus glaucus,Aspergillus flavus, Aspergillus fumigatus, Aspergillus nidulans,Aspergillus niger, Aspergillus terreus, Aspergillus versicolor,Aureobasidium pullulan (Pullularia pullulans), Drechslera sorokiniana,Helminthosporium sativum, Botrytis cinerea, Candida albicans, Chaetomiumglobosum, Cladosporium herbarum, Cladosporium sphaerospennum(Homodendrum hordei), Drechslera spicifera (Curvularia spicifera),Epicoccum nigrum (Epicoccum purpurascens), Epidermophyton floccosum,Fusarium moniliforme, Fusarium solani, Geotrichum candidum, Gliocladiumviride, Helminthosporium solani, Microsporum canis, Mucorcircinelloidesf circinelloides. Mucor circinelloidesf lusitanicus, Mucorplumbous, Mycogone perniciosa, Neurospora intermedia, Nigrospora oryzae,Paecilomyces variotii, Penicillum brevicompactum, Penicillumcamembertii, Penicillum chrysogenum, Penicillum digitatum, Penicillumexpansum, Penicillum notatum, Penicillum roquefortii, Phoma betae, Phomaherbarum, Rhizopus oryzae, Rhizopus stolonifer, Rhodotorulamucilaginosa, Saccharomyces cerevisiae, Scopulariopsis brevicaulis,Serpula lacrymans, Setosphaeria rostrata, Stemphylium botryosum,Stemphylium solani, Trichoderma harzianum, Trichophyton mentagrophytes,Trichophyton rubrum, or Trichothecium roseum. In some embodiments, theallergen is from a smut, for example, Ustilago nuda, Ustilagocynodontis, Ustilago candis, Sporisorium cruentum, Ustilago avenae, orUstilago tritici.

In some embodiments, the allergen analyte is from a grass, for example,Paspalum notatum, Cynodon dactylon, Poa compressa, Bromus inennis,Phalaris arundinacea, Zea cans, Elytrigia repens (Agropyron repens),Sorghum haelpense, Poa pratensis, Festuca pratensis (elatior), Avenasativa, Dactylis glomerata, Agrostis gigantea (alba), Secale cereale,Leymus (Elymus) condensatus, Lolium perenne ssp. multiflorum, Loliumperenne, Anthoxanthum odoratum, Phleum pratense, Holcus lanatus,Triticum aestivum, or Elymus (Agropyron) smithii.

In some embodiments, the allergen analyte is from a weed, for example,Atriplex polycarpa, Baccharis halimifolia, Baccharis sarothroides,Hymenoclea salsola, Amaranthus hybridus, Xanthium strumarium (commune),Rumex crispus, Eupathium capillifolium, Solidago spp., Amaranthustuberculatus (Acnida tamariscina), Allenrolfea occidentalis, Chenopodiumbotrys, Kochia scoparia, Chenopodium album, Iva xanthifolia, Ivaangustifolia, Chenopodium mbrosioides, Artemisia vulgaris, Artemisialudoviciana, Urtica dioica, Amaranthus spinosus, Plantago lanceolata,Iva axillaris, Atriplex lentiformis, Ambrosia dumosa, Ambrosiaacanthicarpa, Ambrosia trifida, Ambrosia artemisiifolia, Ambrosiaconfertiflora, Ambrosia bidentata, Ambrosia psilostachya, Salsola kali(pestifer), Artemisia californica, Artemisiafrigida, Artemisiatridentata, Atriplex wrightii, Atriplex confertifolia, or Artemisiaannua.

In some embodiments, the allergen analyte is from a tree, for example,Acasia spp., Alnus glutinosa, Alnus rubra, Alnus incana ssp. rugosa,Alnus rhombifolia, Fraxinus velutina, Fraxinus pennsylvanica, Fraxinuslatifolia, Fraxinus americana, Populus tremuloides. Myrica cerifera,Fagus grandifolia (americana), Casuarina equisetifolia, Betula lenta,Betula pendula, Betula nigra, Betula occudentalis (fontinalis), Betulapopulifolia, Acer negundo, Cryptomeria japonica, Juniperus ashei(sabinoides), Juniperus virginiana, Tamarix gallica, Populus balsamiferassp. trichocarpa, Populus deltoides, Populusfremontii, Populuswislizeni, Populus monilifera (sargentii), Cupressus arizonoca, Taxodiumdistichum, Cupressus sempervirens, Ulmus americana, Ulmus crassifolia,Ulmus pumila, Eucalyptus globulus, Celtis occidentalis, Corylusamericana, Corylus avellana, Carya ovata, Carya laciniosa, Carya alba,Juniferus monosperma, Juniperus princhotii, Juniperus scopulorum,Juniperus occidentalis, Robinia pseudoacacia, Mangifera indica, Acermacrophyllum, Acer rubrum, Acer saccharum, Melaleuca quinquenervia(leucadendron), Prosopis glandulosa (juliflora), Broussonetiapapyrifera, Morus rubra, Morums alba, Quercus gambelii, Quercusvelutina, Quercus macrocarpa, Quercus kelloggii, Quercus agrifolia,Quercus lobata, Quercus ilex, Quercus stellata, Quercus rubra, Quercusdumosa, Quercus virginiana, Quercus nigra, Quercus garryana, Quercusalba, Olea europaea, Elaegnus angustifolia, Citrus sinensis, Arecastrumromanzoffianum (Cocos plumosa), Carya illnoensis, Schinus molle, Schinusterebinthifolius, Pinus taeda, Pinus strobus, Pinus palustris, Pinusponderosa, Pinus elliottii, Pinus virginiana, Pinus monticola, Pinusechinata, Populus nigra, Populus alba, Ligustrum vulgare, Liquidambarstyraciflua, Platanus occidentalis, Platanus orientalis, Platanusracemosa, Platanus acerifolia, Juglans nigra, Juglans californica,Juglans regia, Salix lasiolepsis, Salix nigra, or Salix discolor.

In some embodiments, the allergen is from a flower, for example,Chrysanthemum leucanthemum, Taraxacum officinale, or Helianthus annuus.In some embodiments, the allergen is from a farm plant, for example,Medicago sativa, Ricinus communis, Trifolium pratense, Brassica spp., orBeta vulgaris.

In some embodiments, the allergen analyte is from plant food (an edibleplant), for example, Prunus dulcis, Malus pumila, Prunus armeniaca, Musaparadisiaca (sapientum), Hordeum vulgare, Phaseolus lanatus, Phaseolusvulgaris, Phaseolus sp., Phaseolus sp., Phaseolus vulgaris, Rubusallegheniensis, Vaccinium sp., Brassica oleracea var. botrytis,Fagopyrum esculentum, Brassica oleracea var. capitata, Theobroma cacao,Cucumis melo, Daucus carota, Brassica oleracea var. botrytis, Apiumgraveolens var. dulce, Prunus sp., Cinnamomum verum, Coffea arabic, Zeacans, Vaccinium macrocarpon, Cucumis sativus, Allium sativum, Zingiberofficinale, Vitis sp., Citrus paradisi, Humulus lupulus, Citrus limon,Lactuca sativa, Agaricus campestris, Brassica sp., Myristica fragrans,Avena sativa, Olea europaea, Allium cepa var. cepa, Citrus sinensis,Vigna unguiculata, Pisum sativum, Prunus persica, Pyrus communis, Pipernigrum, Capsicum annuum var. annuum, Ananas comosus, Ipomoea batatas,Solanum tuberosum, Rubus idaeus var. idaeus, Oryza sativa, Secalecereale, Sesamum orientale (indicum), Glycine max, Spinacia oleracea,Cucurbita pepo var. melopepo, Fragaria chiloensis, Lycopersiconesculentum (lycopersicum), Brassica rapa var. rapa, Vanilla planifolia,Citrullus lanatus var. lanatus, or Triticun aestivum.

In some embodiments the allergen analyte is from fish or shellfish, forexample, Micropterus sp., Ictalurus punctatus, Mercenaria mercenaria,Gadus morhua, Callinectes sapidus, Platichthys sp., Hippoglossus sp.,Homarus americanus, Scomber scombrus, Crassostrea virginica, Sebastesmarinus, Salmo salar, Clupeiformes, Pecten magellanicus, Penaeus sp.,Salvelinus sp., or Thunnus sp. In some embodiments, the allergen is ananimal food product, for example, from Bos taurus, Ovis aries, or Susscrofa. In some embodiments, the allergen is a poultry product, forexample, chicken (Gallus gallus) products or turkey (Meleagrisgallopavo) products. In some embodiments, the allergen is from a dairyproduct, for example, bovine casein or bovine milk. In some embodiments,the allergen is a nut, for example, Bertholletia excelsa, Anacardiumoceidentale, Cocos nucifera, Corylus americana, Arachis hypogaea, Caryaillinoensis, Juglans nigra, or Juglans regia. In some embodiments, theallergen is dust, for example, barley grain dust, corn grain dust, housedust, mattress dust, oat grain dust, wheat grain dust, upholstery dust,or latex dust.

In some embodiments, the antigen analyte is an autoantigen associatedwith an autoimmune disorder. In some embodiments, the autoimmunedisorder is a cell or organ-specific autoimmune disorder, and theautoantigen analyte is selected from among: acetylcholine receptor(myasthenia gravis), actin (chronic active hepatitis, primary biliarycirrhosis), adenine nucleotide translocator (ANT) (dilatedcardiomyoapthy, myocarditis), beta-adrenoreceptor (dilated-degree.cardiomyopathy), aromatic L-amino acid decarboxylase (autoimmunepolyendocrine syndrome type I (APS-1)), asialoglycoprotein receptor(autoimmune hepatitis), bactericidal/permeability-increasing protein(Bpi) (cystic fibrosis vasculitides), calcium-sensing receptor (acquiredhypoparathyroidism), cholesterol side-chain cleavage enzyme (CYPIIa)(APS-1), collagen type IV alpha3-chain (Goodpasture syndrome),cytochrome P450 2D6 (CYP2D6) (autoimmune hepatitis), desmin (Crohndisease, coronary artery disease), desmoglein 1 (pemphigus foliaceus),desmoglein 3 (pemphigus vulgaris), F-actin (autoimmune hepatitis), GMganglioside (Guillain-Barre syndrome), glutamate decarboxylase (GAD65)(type 1 diabetes, stiff man syndrome), glutamate receptor (GLUR)(Rasmussen encephalitis), H/K ATPase (autoimmune gastritis),17-alpha-hydroxylase (CYP17) (APS-1), 21-hydroxylase (CYP21) (Addisondisease), IA-2 (ICA512) (type 1 diabetes), insulin (type 1 diabetes,insulin hypoglycemic syndrome (Hirata disease), type B insulinresistance, acanthosis, systemic lupus erythematosus (SLE)), intrinsicfactor type 1 (pernicious anemia), leukocyte function-associated antigen(LFA-1) (treatment-resistant lyme arthritis), myelin-associatedglycoprotein (MAG) (polyneuropathy), myelin basic protein (multiplesclerosis, demyelinating disease), myelin oligodendrocyte glycoprotein(MOG) (multiple sclerosis), myosin (rheumatic fever), p-80-Coilin(atopic dermatitis), pyruvae dehydrogenase complex-E2 (PDC E2) (primarybiliary cirrhosis), sodium iodide symporter (NIS) (Graves disease,autoimmune hypothyroidism), SOX-10 (vitiligo), thyroid and eye muscleshared protein (autoimmune thyroiditis), thyroid peroxidase (autoimmuneHashimoto thyroiditis), thyrotropin receptor (Graves disease), tissuetransglutaminase (celiac disease), transcription coactivator p75 (atopicdermatitis), tryptophan hydroxylase (APS-1), tyroisinase (vitiligo,metastatic melanoma), and tyrosine hydroxylase (APS-1), wherein theassociated autoimmune disorder(s) is listed parenthetically immediatelyafter each autoantigen analyte.

In some embodiments, the autoimmune disorder is a systemic autoimmunedisorder, and the autoantigen analyte is selected from among: ACTH (ACTHdeficiency), aminoacyl-tRNA histidyl synthetase (myositis,dermatomyositis), aminoacyl-tRNA synthetase (polymyositis,dermatomyositis), cardiolipin (SLE), carbonic anhydrase II (SLE, Sjogrensyndrome, systemic sclerosis), collagen (rheumatoid arthritis (RA), SLE,progressive systemic sclerosis), centromere-associated protein (systemicsclerosis), DNA-dependent nucleosome-stimulated ATPase(dermatomyositis), fibrillarin (scleroderma), fibronectin (SLE, RA,morphea), glucose-6-phosphate isomerase (RA), Beta2-glycoprotein I(Beta2-GPI) (primary antiphospholipid syndrome), golgin (95, 97, 160,and/or 180) (Sjogren syndrome, SLE, RA), heat shock protein (variousimmune related disorders), hemidesmosomal protein 180 (bullouspemphigoid, herpes gestationis, cicatricial pemphigoid, histoneH2A-H2B-DNA (SLE), IgE receptor (chronic idiopathic urticaria), keratin(RA), Ku-DNA-protein kinase (SLE), Ku-nucleoprotein (connective tissuesyndromes), La phosphoprotein (La 55-B) (Sjoren syndrome),myeloperoxidase (necrotizing and cescentic glomerulonephritis (NCGN),system vasculitis), proteinase 3 (PR3) (Wegener granulomatosis,Churg-Strauss syndrome), RNA polymerase I-III (RNP) (systemic sclerosis,SLE), signal recognition protein (SRP54) (polymyositis), topoisomerase-1(Scl-70) (scleroderma, Raynaud syndrome), tubulin (chronic liverdisease, visceral leishmaniasis), and vimentin (systemic autoimmunedisease), wherein the associated autoimmune disorder(s) is listedparenthetically immediately after each autoantigen.

In some embodiments, the autoimmune disorder is a plasma proteinautoimmune disorder or cytokine autoimmune disorder, and the autoantigenanalyte is selected from among: C1 inhibitor (autoimmune C1 deficiency),Clq (SLE, membrane proliferative glomerulonephritis (MPGN)), cytokine(e.g., IL-1 alpha, IL-1beta, IL-, IL-10, LIF) (RA, systemic sclerosis),factor II (prolonged coagulation time), factor V (prolonged coagulationtime), factor VII (prolonged coagulation time), factor VIII (prolongedcoagulation time), factor IX (prolonged coagulation time), factor X(prolonged coagulation time), factor XI (prolonged coagulation time),factor XII (prolonged coagulation time), thrombin (prolonged coagulationtime), vWF (prolonged coagulation time), glycoprotein IIb/IIIg and Ib/IX(autoimmune thrombocytopenia purpura), IgA (immunodeficiency), andoxidized LDL (OxLDL) (atherosclerosis), wherein the associatedautoimmune disorder(s) is listed parenthetically immediately after eachautoantigen analyte.

In some embodiments, the autoimmune disorder is a cancer orparaneoplastic autoimmune disorder, and the autoantigen analyte isselected from among: amphiphysin (neuropathy, small lung cell cancer),cyclin B 1 (hepatocellular carcinoma), DNA topoisomerase II (livercancer), desmoplakin (paraneoplastic pemphigus), gephyrin(paraneoplastic stiff man syndrome), Hu protein (paraneoplasticencephalomyelitis), neuronal nicotinic acetylcholine receptor (subacuteautonomic neuropathy, cancer), p53 (cancer, SLE), p62 (IGF-IImRNA-binding protein) (hepatocellular carcinoma), recoverin(cancer-associated retinopathy), R1 protein (paraneoplastic opsoclonusmyoclonus ataxia), beta IV spectrin (lower motor neuron syndrome),synaptotagmin (Lambert-Eaton myasthenic syndrome), voltage-gated calciumchannels (Lambert-Eaton myasthenic syndrome) and Yo protein(paraneoplastic cerebellar degeneration).

In some embodiments, the antigen analyte is an endogenous antigen thatis an aberrantly expressed polypeptide. Examples of such endogenousantigens include, but are not limited to, amyloid beta (A-beta orA.beta.), alpha synuclein, cystatin C, tau, ABri, ADan, superoxidedismutase (SOD), mutant Huntington, PrP.sup.sc or a fragment of any ofthe foregoing.

In some embodiments of the invention, the analyte comprises at least oneepitope of an implant to be introduced into a subject, metabolic ordegradation products of an implant material, or substances thatspecifically bind to an epitope of an implant material, such asantibodies developed to an implant material or its degradation productsSuch implants can include, for example, electrically powered implants(for example, artificial pacemakers), bioimplants (biomaterialsurgically implanted in a subject's body to replace damaged tissue (forexample, orthopedic reconstructive prosthesis), cardiac prostheses(artificial valves), skin, and cornea), contraceptive implants, dentalimplants, orthopedic implants, and adhesion prevention devices. Examplesof implant materials that can bear epitopes include latex; silicone;metals, such as cobalt chrome (Co—Cr) alloys, titanium, and titaniumalloys: polymers, such as ultra-high molecular weight polyethylene(UHMWPE) and polymethyl methacrylate cement (PMMA); and bioceramics,such as hydroxyapatite and Bioglass.

Non-Antibody Signal Transducing Element

Exemplary embodiments of the present invention include variousnon-antibody signal transducing elements. Each signal transducingelement is adapted to receive, i.e., bind, a detector molecule that isitself adapted to receive, i.e., bind, a specific analyte of interest.In one embodiment, the signal transducing element is a transmembranechimeric fusion protein that is engineered into and expressed on thesurface of the biosensor cell, and that is adapted to activate thesignal transduction pathway that ultimately results in the reporterprotein emitting a detectable signal. In another embodiment, the signaltransducing element is a soluble chimeric fusion protein that is adaptedto bind to a cell surface signal transducer, such as a native receptoror receptor protein that is adapted to activate the signal transductionpathway that ultimately results in the reporter protein emitting adetectable signal. In still another embodiment, the signal transducingelement is a soluble chimeric fusion protein that is engineered into andexpressed by the biosensor cell. The soluble chimeric fusion protein isthen secreted/excreted into the extracellular space where it binds to acell surface signal transducer, such as a native receptor or receptorprotein that is adapted to activate the signal transduction pathway thatultimately results in the reporter protein emitting a detectable signal.

The chimeric fusion proteins of this invention may include: (i) acomponent of a protein that is adapted to bind to the at least one typeof detector molecule (e.g., a soluble antibody); and (ii) a component ofa receptor complex normally expressed by the living, engineeredbiosensor cell. In some embodiments, the component of the protein thatis adapted to bind to the at least one type of detector molecule may bederived from a bacterial binding protein (i.e., an antibody bindingprotein derived from a bacteria) such as, for example, the IgG bindingdomain of a strep G protein (referred to herein as IgGbp or Igbp in theFigures). Tandem repeats of this IgG binding domain may be included toincrease the affinity of the binding protein for the soluble antibody.In an alternate embodiment, the component of the chimeric fusion proteinthat is adapted to bind to the at least one type of detector molecule isan antibody binding domain derived from a receptor protein such as, forexample, the murine Fc gamma RI (FcγRI) receptor. In various exemplaryembodiments, the component of the receptor complex normally expressed bythe living, engineered biosensor cell is IgM (for B cell biosensors);Igα/β (for B cell biosensors); IgE (for mast cell biosensors); CD19 (forB cell biosensors), CD3zeta (for T cell biosensors), or FcRI (for mastcell biosensors).

The non-antibody signal transducing elements of this invention mayinclude either complete protein sequences or engineered proteinfragments such as selected protein domains derived from larger proteinmolecules. One of ordinary skill in the art will appreciate thatfragments of larger molecules may be created using standard geneticengineering techniques such as synthetic gene technology. When fragmentsof larger proteins are used to engineer antibody binding motifs asaspects of chimeric fusion proteins it is important to design theengineered proteins to ensure proper conformational folding of theselected protein fragments. Therefore, it is useful to include (in thefusion proteins) short spacer or linker elements that do not readilyform protein secondary structures. Short combinations of amino acidssuch as glycine, serine and alanine, for example, may be used for thesespacer or linker elements. In an exemplary embodiment, the amino acidsequence glycine (G), serine (S), alanine (A), serine (S), glycine (G),serine (S), glycine (G) is used to separate a binding domain from acomponent of a receptor complex in an engineered protein molecule (seeSEQ ID NO: 19). With regard to the peptide linker or spacer used toconnect the detector element to the signal-transducing element orinterconnect different segments of a signal-transducing element: thelinker typically joins the carboxyl terminus of one element to the aminoterminus of another. Peptide linkers may vary from 0 to 25 amino acidsin length or any intermediate integer value and typically, but notalways, comprise hydrophilic amino acids such as glycine (G) and serine(S).

As previously stated, each signal transducing element binds to adetector molecule that binds to a specific analyte of interest. Adetector molecule that has bound to an analyte will either (i) bind to atransmembrane signal transducing element; or (ii) to a signaltransducing element that will itself bind to a cell surface signaltransducer (e.g., native receptor). In the first situation, upon thebinding of a sufficient number of analytes to a sufficient number ofdetector molecules that are themselves bound to transmembranenon-antibody signal transducing elements, an aggregation of signaltransducing elements occurs on the biosensor cell surface, the signaltransduction pathway is activated, the biological process occurs, andthe detectable signal is emitted by the reporter protein. In the secondcase, upon the binding of a sufficient number of analytes to asufficient number of detector molecules to a sufficient number ofnon-antibody signal transducing elements that are themselves bound tothe appropriate native receptor, an aggregation of the receptors occurson the cell surface, the signal transduction pathway is activated, theincrease in intracellular calcium occurs, and detectable light isemitted by the reporter protein.

A first non-antibody signal transducing element in accordance with anexemplary embodiment of the present invention includes a bacterialbinding protein (IgGbp) fused to the IgM heavy chain constant domain (Bcell) with a GSASGSG linker. SEQ ID NO: 1 provides the DNA sequence forsignal transducing element IgGbp-IgM and SEQ ID NO: 2 provides theprotein sequence for signal transducing element IgGbp-IgM.

A second non-antibody signal transducing element in accordance with anexemplary embodiment of the present invention includes a bacterialbinding protein (IgGbp) fused to the Igα/β component of the B cellreceptor with a GSASGSG linker. SEQ ID NO: 3 provides the DNA sequencefor signal transducing element IgGbp-Igα/β and SEQ ID NO: 4 provides theprotein sequence for signal transducing element IgGbp-Igα/β.

A third non-antibody signal transducing element in accordance with anexemplary embodiment of the present invention includes a bacterialbinding protein (IgGbp) fused to the CD3 zeta chain of the T-cellreceptor with a GSASGSG linker. SEQ ID NO: 5 provides the DNA sequencefor signal transducing element IgGbp-CD3ζ and SEQ ID NO: 6 provides theprotein sequence for signal transducing element IgGbp-CD3ζ.

A fourth non-antibody signal transducing element in accordance with anexemplary embodiment of the present invention includes the FcγRIantibody binding domain fused to the IgM heavy chain constant domain (Bcell) with a GSASGSG linker. SEQ ID NO: 7 provides the DNA sequence forsignal transducing element FcγRI-IgM and SEQ ID NO: 8 provides theprotein sequence for signal transducing element FcγRI-IgM.

A fifth non-antibody signal transducing element in accordance with anexemplary embodiment of the present invention includes the FcγRIantibody binding domain fused to the Igα/β component of the B-cellreceptor with a GSASGSG linker. SEQ ID NO: 9 provides the DNA sequencefor signal transducing element FcγRI-Igα/β and SEQ ID NO: 10 providesthe protein sequence for signal transducing element FcγRI-Igα/fβ.

A sixth non-antibody signal transducing element in accordance with anexemplary embodiment of the present invention includes the FcγRIantibody binding domain fused to the CD3 zeta chain of the T-cellreceptor with a GSASGSG linker. SEQ ID NO: 11 provides the DNA sequencefor signal transducing element FcγRI-CD3ζ and SEQ ID NO: 12 provides theprotein sequence for signal transducing element FcγRI-CD3Cζ.

A seventh exemplary non-antibody signal transducing element inaccordance with the present invention includes a bacterial bindingprotein (IgGbp) fused to the IgE constant domain (B cell) with a GSASGSGlinker. SEQ ID NO: 13 provides the DNA sequence for signal transducingelement IgGbp-IgE and SEQ ID NO: 14 provides the protein sequence forsignal transducing element IgGbp-IgE.

An eighth exemplary non-antibody signal transducing element inaccordance with the present invention includes the FcγRI antibodybinding domain fused to the IgE constant domain (B cell) with a GSASGSGlinker. SEQ ID NO: 15 provides the DNA sequence for signal transducingelement FcγRI-IgE and SEQ ID NO: 16 provides the protein sequence forsignal transducing element FcγRI-IgE.

A ninth exemplary non-antibody signal transducing element in accordancewith the present invention includes monomeric streptavidin fused to theCD3 zeta chain of the T-cell receptor with a GSASGSG linker. SEQ ID NO:17 provides the DNA sequence for signal transducing element mSA-CD3ζ andSEQ ID NO: 18 provides the protein sequence for signal transducingelement mSA-CD3ζ. Monomeric streptavidin is a recombinant form ofstreptavidin that includes mutations that break the streptavidintetramer into a monomer and to enhance the solubility of the resultantisolated subunit.

EXAMPLE BIOSENSOR I

With reference to FIGS. 1a-b , a first biosensor 100 in accordance withan exemplary embodiment of the present invention includes Jurkat T cells102 that have been engineered to produce aequorin 104 and that have beencharged with CTZ 106 to form an aequorin/CTZ complex, as previouslydescribed. This particular biosensor has also been engineered to expressthe transmembrane non-antibody signal transducing element 108, which isIgGbp-CD3ζ (SEQ ID NOS: 5-6), although the transmembrane non-antibodysignal transducing element FcγRI-CD3 ζ (SEQ ID NO: 11-12) may also beused with biosensor 100. Biosensor cell 102 also includes at least onesignal transduction pathway 110, the activation of which results in anincrease of intracellular Ca2+ 112. As shown in FIG. 1b , when asufficient number of detector molecules 114 (e.g., soluble antibodies)to which target analyte 116 (e.g., E. coli O157) is bound bind totransmembrane non-antibody signal transducing elements 108, signaltransduction pathway 110 is activated, intracellular Ca2+ 112 increases,the aequorin/CTZ complex undergoes a conformational change and emits asignal (photon) of light 118 which is detected by photo multiplier tube120, and spike 122 is graphically displayed on a testing device (seedescription below), indicating the presence of target analyte 116 withina sample being tested. The display may be both qualitative andquantitative with regard to target analyte 116.

EXAMPLE BIOSENSOR II

With reference to FIGS. 2a-b , a second biosensor 200 in accordance withan exemplary embodiment of the present invention includes MC/9(ATCC®CRL-8306™) mast cells 202 that have been engineered to produceaequorin 204 and that have been charged with CTZ 206 to form anaequorin/CTZ complex, as previously described. This particular biosensorexpresses the native Fc epsilon receptor (i.e., FcεRI) 207, which bindsto soluble non-antibody signal transducing element 208, which isIgGbp-IgE (SEQ ID NOS: 13-14), although the non-antibody signaltransducing element FcγRI-IgE. (SEQ ID NO: 15-16) may also be used withbiosensor 200. As shown in FIG. 2b , when a sufficient number ofdetector molecules 214 (e.g., soluble antibodies) to which targetanalyte 216 (e.g., E. coli O157) is bound bind to non-antibody signaltransducing elements 208 that have previously bound to native Fc epsilonreceptors 207, signal transduction pathway 210 is activated,intracellular Ca2+ 212 increases, the aequorin/CTZ complex undergoes aconformational change and emits a signal (photon) of light 218 which isdetected by photo multiplier tube 220, and spike 222 is graphicallydisplayed on a testing device (see description below), indicating thepresence of target analyte 216 within a sample being tested. The displaymay be both qualitative and quantitative with regard to target analyte216.

EXAMPLE BIOSENSOR III

With reference to FIGS. 3a-b , a third biosensor 300 in accordance withan exemplary embodiment of the present invention includes MC/9 (ATCC®CRL-8306™) mast cells 302 that have been engineered to produce aequorin304 and that have been charged with CTZ 306 to form an aequorin/CTZcomplex, as previously described. This particular biosensor expressesthe native Fc epsilon receptor (i.e., FcεRI) 307, which binds tonon-antibody signal transducing element 308, which is IgGbp-IgE (SEQ IDNOS: 13-14), although the non-antibody signal transducing elementFcγRI-IgE. (SEQ ID NO: 15-16) may also be used with biosensor 300. Inthis particular embodiment, biosensor cells 302 have been furtherengineered to express IgGbp-IgE and excrete this non-antibody signaltransducing element into the extracellular space, wherein it binds tothe native FcεRI expressed on the cell surface. As shown in FIG. 3b ,when a sufficient number of detector molecules 314 (e.g., solubleantibodies) to which target analyte 316 (e.g., E. coli O157) is boundbind to non-antibody signal transducing elements 308 that havepreviously bound to native Fc epsilon receptors 307, signal transductionpathway 310 is activated, intracellular Ca2+ 312 increases, theaequorin/CTZ complex undergoes a conformational change and emits asignal (photon) of light 318 which is detected by photo multiplier tube320, and spike 322 is graphically displayed on a testing device (seedescription below), indicating the presence of target analyte 316 withina sample being tested. The display may be both qualitative andquantitative with regard to target analyte 316.

EXAMPLE BIOSENSOR IV

With reference to FIGS. 4, a fourth biosensor 400 in accordance with anexemplary embodiment of the present invention includes biosensor cells402 that have been engineered to produce aequorin and to expresstransmembrane non-antibody signal transducing element 408, which ismSA-CD3 (SEQ ID NO: 17-18). Non-antibody signal transducing elementmSA-CD3ζ (monomeric streptavidin-CD3ζ) binds to a biotinylated detectormolecule 414, which specifically binds to a target molecule 416 such as,for example, epidermal growth factor (EGF). An anti-target moleculeantibody 417 such as, for example, anti-EGF, creates target multimersthat cluster multiple signal transducing elements and induce signaltransduction as previously described. In other embodiments, themonomeric streptavidin component is replaced with a biotinylatedcomponent and alternate linkage means may be employed.

EXAMPLE BIOSENSOR V

With reference to FIG. 5, a fifth biosensor 500 in accordance with anexemplary embodiment of the present invention includes biosensor cells502 that have been engineered to produce aequorin and to expresstransmembrane non-antibody signal transducing element 508, which ismSA-CD3ζ (SEQ ID NO: 17-18). Non-antibody signal transducing elementmSA-CD3ζ (monomeric streptavidin-CD3ζ) binds to a biotinylated detectormolecule 514, which in some embodiments is an autoantigen molecule.Biotinylated detector molecule 514 specifically binds to a targetmolecule 516, which in some embodiments is an anti-autoantigen molecule.Autoantibodies in a serum sample create target multimers that clustermultiple signal transducing elements and induce signal transduction aspreviously described. In other embodiments, the monomeric streptavidincomponent is replaced with a biotinylated component and alternatelinkage means may be employed.

The amino acid sequences of the signal-transducing polypeptide used toproduce the chimeric proteins of the invention may have at least 70%,75%, 80%, 85%, 87.5%, 90, 92.5%, 95%, 97.5%, 98%, 99% sequence identityor similarity to the proteins or domains identified by or in thefollowing accession numbers: IgM heavy chain (GenBank: CAC20458.1),Ig-alpha (P11912.2, GI:547896), Ig-beta (P40259.1 GI:728994), CD19(AAA69966.1 GI:901823), CD3zeta (P20963.2, GI: 23830999), IgE alpha(1F2Q_A, GI:9257150) and Fc-epsilonR1subunit alpha (P12319.1, GI:119865).

Staphylococcus aureus Protein A (P02976.3, GI: 110283003) is encoded bythe spa gene of Staphylococcus aureus and its structure, including itsIg-binding segments, and immunoglobulin-binding properties arewell-known and are incorporated by reference to Graille, et al., ProcNatl Acad Sci USA. 2000 May 9; 97(10):5399-404; and Roben, et al. JImmunol. 1995 Jun. 15; 154(12):6437-45. Variants of Protein A or itsimmunoglobulin-binding segments having at least 700%, 75%, 80%, 85%,87.5%, 90%, 92.5%, 95%, 97.5%, 98%, 99% sequence identity or similarityto known Protein A amino acid sequences and the capacity to bind to animmunoglobulin or other analyte, such as those described by Graille, etal. and Roben, et al., may be produced by molecular biologicaltechniques well-known in the art including by direct synthesis of anucleic acid encoding an immunoglobulin-binding amino acid sequence.

Other bacterial immunoglobulin-binding proteins, such as StreptococcusProtein G and engineered variants of such proteins, are known and areincorporated by reference to Bailey, et al., J Immunol Methods. 2014Dec. 15; 415:24-30 (doi: 10.1016/j.jim.2014.10.003) (Epub 2014 Oct. 22);and to Watanabe, et al., J Biol Chem. 2009 May 1; 284(18):12373-8 (doi:10.1074fjbc.M809236200)(Epub 2009 Mar., 6,). Variants of Protein G orits immunoglobulin-binding segments having at least 70%, 75%, 80%, 85%,87.5%, 90/%, 92.5%, 95%, 97.5%, 98%, 99% sequence identity or similarityto known Protein G amino acid sequences and the capacity to bind to animmunoglobulin or other analyte, such as those described by Bailey, etal. and Watanabe, et al. may be produced by molecular biologicaltechniques well-known in the art including by direct synthesis of anucleic acid encoding an immunoglobulin-binding amino acid sequence.

Fc receptors (FcR) bind to the Fc portion of an immunoglobulin and manytypes such Fc receptors are known, including FcγRI and FcεRI. Thestructural and functional binding characteristics of these FcRs areincorporated by reference to Fridman, FASEB J. 1991 September;5(12):2684-90. Variants of FcRs or their immunoglobulin-binding segmentshaving at least 70%, 75%, 80%, 85%, 87.5%, 90%, 92.5%, 95%, 97.5%, 98%,99% sequence identity or similarity to a known FcR amino acid sequence,such as a sequence described by Fridman, may be produced by molecularbiological techniques well-known in the art including by directsynthesis of a nucleic acid encoding an immunoglobulin-binding aminoacid sequence.

A signal transducing protein according to the invention may have atleast 70%, 75%, 80%, 85%, 87.5%, 90%, 92.5%, 95%, 97.5%, 98%, 99%sequence identity or similarity to the disclosed chimeric signaltransducing proteins described by SEQ ID NOS: 2, 4, 6, 8, 10, 12, 14,16, and 18 and also have the ability to bind an analyte, such as animmunoglobulin, and then transduce a signal into the engineeredbiosensor cell. Such variants may be constructed by methods well knownin the molecular biological arts or by chemical synthesis ofpolynucleotides encoding the variant chimeric reporter proteins,insertion of the encoding sequences into a vector, and transformation ortransfection of a competent cell with the vector.

Cell Sorting and Cloning

The design and construction of the biosensors of this invention resultedin a mixed population of biosensor cells when cultured. Some cells didnot express the engineered factors while others expressed the factors atvarying levels. Following successful electroporation and gene insertion,biosensor cells were cultured and tested for biological response (flashsignal) as mixed populations. Single cell sorting was performed using aFlow Cytometer. Cells were isolated and then expanded for analysis toselect those that expressed high levels of the desired proteins. Forthis process, fluorescently labeled antibodies were used to targetdifferent receptors on the biosensor cells, thereby enabling the sortingprocess. Individual clones were screened for signaling and the bestclones were selected. Through this process, the most suitable cloneswere identified and isolated. Fluorescence-Activated Cell Sorting (FACS)and live cell staining for extracellular protein was conducted asdescribed below.

Engineered biosensor cells were counted, gently centrifuged, andre-suspended in wash buffer (HBSS+2% BSA) to a final concentration of1×10⁷-1×10⁸ cells/mL. In each experiment, either a full antibody withthe Fc region or F(ab)₂ was used. When using the full antibody, 1-0.5 μgof Fc receptor blocking antibody was added to each empty 12×15 mm tubethat was to receive cells. Into each of these tubes, 100 μL of cells(1×10⁶ to 1×10⁷ cells) was added on top of the Fc blocking antibody.Cells were mixed gently and incubated for 15 minutes at 4° C. or roomtemperature. When using F(ab)2, the previous step of blocking Fc wasomitted. A total of 1 μg of primary antibody (against the receptor ofchoice) was added, and the cells were then mixed gently beforeincubating for 20-40 minutes on ice (or at 4° C.). This temperatureprevented receptor internalization. Cells were gently agitated (swirled)intermittently to encourage labeling. A 2 mL volume of cold wash bufferwas added then cells were centrifuged at 4° C. and the supernatantdiscarded. The wash step was repeated before re-suspending cells in 100μL of wash/sorting buffer. A secondary FITC-labeled antibody was added(0.5-1 μg) to the cells and mixed before incubating on ice (or at 4° C.)for 20-40 minutes. Cells were protected from light during the entireprocess. A 2 mL volume of cold wash buffer was added then cellscentrifuged and supernatant discarded. The wash step was repeated andcells re-suspend in 0.5-1 mL of wash buffer. Cells were incubated on iceuntil the time for sorting. Sorting was done as soon as possible (atleast on the same day). Cloning and culturing cells after single cellsorting was conducted as described below.

Biosensor cells were sorted into 96 well plates with each wellcontaining one cell and 100-200 μL cell growth media. Plates werescanned/monitored for the next 10 to 14 days to determine the rate ofgrowth and to judge when to transfer to a 24 well plate. Duringscanning, different markings were used for different conditions. Somewells were marked if they contained live cells, but were not ready fortransfer and contaminated wells were also marked. Cells were transferredto a 24 well plate containing 1.0 mL of the appropriate media in eachwell. In cases of contaminated cells, washing was done by adding all ofthe cell suspension from a well into 5 ml of sterile 1x PBS in a 15 mLconical tube. Cells were then centrifuged at 170 RCF for 10 minutes andthe supernatant discarded. The pellet was re-suspended in 1.0 mL offresh media in a 24 well plate to be cultured. Following continuedgrowth, cells were transferred to a 12 well plate with 1.5 mL of freshmedia per well.

For clone screening, after growing in a 12 well plate, cells werecounted to determine if they were ready for charging and flash testing.During flash testing, a single iteration involved 25,000 cells. Enoughcells were grown to accommodate testing and also leave some to continuegrowing. This step marked the first round of clone screening. Selectedclones were grown further and subjected to subsequent tests depending onthe desired properties. For biological response, for example,Jurkat-FcγRI-CD3ζ clones were screened using anti-CD3ε antibodies(positive control) and monoclonal antibodies against bacteria with therespective bacteria while Digitonin was used for chemical response test.MC/9-Aeq clones were screened using anti-FcεRI antibodies (biologicalresponse) and Digitonin (chemical response).

In summary, fluorescence-activated cell sorting (FACS) was performedusing fluorescent antibody labels to select and isolate cells which werehighly expressing the desired proteins, which in this case were theengineered receptors. This process resulted in a population ofhighly-expressing biosensor cells which was further confirmed by flashtesting using the PMT in the testing device. During the entire process,cells were counted using an automatic cell counter to eliminate humanerror and enhance consistency and efficiency. Different clones ofJurkat-FcγRI-CD3ζ gave different levels of biological response whentested with Anti-E. coli O111 mAb and E. coli O111 bacteria. Many cloneswere tested the same way and the highest responders were saved in aclone bank. Likewise, chemical response results obtained from testingdifferent MC/9-Aeq clones using the chemical Digitonin indicated thatdifferent clones gave different levels of chemical response depending onthe level of Aequorin expression. The clones with the highest signalwere saved in the clone bank.

Culturing Biosensor Cells

Different culture media formulations were used for different cell linesto ensure optimal growth conditions. MC/9 mast cells were cultured inComplete Mast Cell Media (DMEM—Sigma, Cat. No. D5796: 1x Pen/Strep; 10%FBS; 10% T-Stim Supplement; 50 μM β-mercaptoethanol). Jurkat T-cellswere cultured in complete RPMI media (RPMI-ThermoFisher; 10% FBS; 1xPen/Strep). Depending on the characteristics of the electroporatedconstructs, different antibiotics were used for selection in cellculture. Appropriate antibiotics were added to the growth media 2-3 daysafter electroporation to select for cells that had successfullyintegrated the linearized DNA constructs. Cell concentration was keptbetween 4.0×10⁵ and 1.0×10⁶ cells/mL for optimal cell growth. Differentcell lines and clones were processed for long term storage and stockswere frozen in liquid nitrogen as follows: (i) cells were centrifuged at150 RCF for 10 minutes and the supernatant was discarded; (ii) the cellpellet was re-suspended in freezing media (RPMI; 50% FBS; 10% DMSO) at aconcentration of 5.0×10⁵ cells/mL: and (iii) volumes of 1 mL werealiquoted into 2 mL Nunc Cryo-vials and frozen at −80° C. for 24 hoursbefore being transferred to liquid nitrogen for long term storage.

Charging Biosensor Cells

The biosensor cells of this invention were centrifuged in 50 mL conicaltubes at 150 RCF for 10 minutes. The supernatant was discarded andpellet re-suspended in charging media (RPMI; 10% antibody-depleted FBS;1x pen/strep; 0.1% Pluronic F68 and 1.5 mM coelenterazine) at aconcentration of 25,000 cells/180 μL. Additionally, cells were also beencharged at different concentrations such as, for example, 100,000cells/180 μL and 400,000 cells/180 μL. Cells were charged at roomtemperature with gentle shaking/rocking for 24-26 hours. Before use, thecommercially available antibody-depleted FBS may be purified furtherusing other antibody depletion systems.

Concentrating Cells

The biosensor cells of this invention were demonstrated to be moreeffectively charged at lower concentrations rather than higherconcentrations. For example, charging cells at a density of 25,000cells/180 μL versus 400,000 cells/180 μL was shown to result in atwo-fold increase in detectable signal. Jurkat-FcγRI-CD3ζ clone P5G7cells were charged at both 400,000 cells/180 μL and 25,000 cells/180 μLthen tested at 400,000 cells/180 μL in each reaction. Overnight E. coliO111 bacteria culture was used with 23 nM anti-E. coli O111 mAb.Biosensor cells charged at a lower concentration gave a higher signalfor the same number of bacteria cells tested. Biosensor cell density ismostly changed by concentrating the cells after charging to allow foroptimal pathogen detection. Different concentrations were used forpathogen detection depending on the target pathogen and quality of theantibody, when the detector molecule is a soluble antibody. Biosensorcells are concentrated by centrifugation at 150 RCF for 10 minutes andthe cell pellet is re-suspended in the desired volume of the testingmedium. The charging medium may also serve as the testing medium. Incertain instances, addition of normal FBS to the media triggered abiological response resulting in a biosensor signal (flash) due to highconcentration of antibodies in normal FBS. Therefore, commerciallyavailable antibody-depleted FBS was used in the charging process, whichreduced the antibody triggered signal without totally eliminating it.Additional methods were used to further deplete traces of antibodies inthe commercially available antibody-depleted FBS.

Bioassay

In exemplary embodiments of this invention, the analyte bioassay isformatted with the biosensor cell and a soluble monoclonal antibody(mAb) that is specific for that analyte (e.g., pathogen). In theseembodiments, the specificity of the bioassay is directly related to theselective binding of the soluble antibody to the target analyte and thespecificity and sensitivity of the biosensor is determined by detectionand measurement of bioluminescence. In this process, biosensor cells areinitially charged using the light-emitting molecule, coelenterazine(CTZ). The soluble antibody of choice and the sample being analyzed arethen added. If a target pathogen is present in the sample, it interactswith the soluble antibody, which binds to a fusion protein expressed bythe biosensor cell, ultimately triggering a signal cascade that resultsin light emission from the biosensor cell. The emitted light is detectedby a photo multiplier tube (PMT) in the testing device and the signalemitted by the biosensor cell is displayed as photon counts per second.As described below, various methods have been developed to detectpathogens based on the soluble antibody and the target pathogen. Threesuch methods, described in detail below, include: (i) instant additionof detector molecules (e.g., antibodies); (ii) coating biosensor cellswith detector molecules (e.g., antibodies); and (iii) coating analytes(e.g., bacteria) with antibodies.

Testing Unit

The bioassay aspect of the present invention herein may be carried outin a testing subunit or test cartridge designed for use with a bench-topor portable testing system and device such as that disclosed in U.S.patent application Ser. No. 13/711,296 (U.S. Pat. No. 9,023,640), whichis incorporated by reference herein, in its entirety. The testcartridge, which may be a single-use, disposable item, receives both thesample and the biosensor and introducing the biosensor into the testcartridge mixes the sample and the biosensor in a predictable andcontrolled manner. The test cartridge further includes a reactionchamber for receiving the test sample and the biosensor, wherein thereaction chamber has a predetermined internal geometry and has beenfurther adapted to minimize or eliminate background noise for thepurpose of improving the overall signal to noise ratio. At least onestabilizer may be located in the reaction chamber for minimizing shearforce damage to the test sample and biosensor during the mixing process.

In an exemplary embodiment, the reaction chamber and fluid channels thatlead to the reaction chamber within the test cartridge are designed toachieve several objectives. An inlet channel for fluid entering thereaction chamber includes a tubular shape and the diameter of the tubeis relatively small and tapers to become smaller at the inlet to thereaction chamber. This increases the velocity of fluid entering thereaction chamber and promotes more vigorous and homogenous mixing due tothe bulk motion of the reagents within the reaction chamber. It isdesirable to mix the reagents and sample in a way to promote mixingbeyond molecular diffusion, in order to minimize the duration of thetest by ensuring that any infectious agent present in the sample rapidlyencounters the biosensor. The inlet channel may be offset from thecentral axis of the reaction chamber to promote a clockwise orcounterclockwise rotational motion of the reagents around the centralaxis of the test chamber as the fluids are mixed in order to increasehomogeneity of the mixture. The inlet channel is also approximatelytangent to the interior surface of the reaction chamber for allowingincoming fluid to travel from the inlet channel to the reaction chamberwhile remaining in contact with the side surface of the reactionchamber, which allows for a minimally turbulent flow and minimalintroduction of air bubbles into the mixed fluids. Bubbles areundesirable due to the unpredictable refraction of light they cause aslight emitted by the reagents travels through bubbles within the mixedreagents or on the surface of the mixed reagents. The axis of the inletchannel may be angled above horizontal (e.g., about 30 degrees) toprovide a partially downward direction to the incoming fluid flow toensure that the reagent is mixed with the fluid residing at the bottomof the reaction chamber. Alternatively, the reagents may be introducedto the test chamber using alternative fluid delivery means such as avertical channel to deliver the reagents to the bottom of the reactionchamber, or delivering the fluid directly on the central axis of thetest chamber in order to create a column of reagent flowing into thetest chamber thereby promoting mixing through entrainment.

The shape (i.e., predetermined geometry) of the reaction chamber may bea revolved section facilitating clockwise or counterclockwise motion ofthe mixing fluids around the central axis of the reaction chamber.Alternatively, if desired, a reaction chamber shape other than arevolved section such as a rectangular or irregular shape may beutilized. In one embodiment, the revolved section used to form thereaction chamber is a portion of an ellipse for facilitating thecollection of stray light emitted by the reagents and reflecting thislight toward the surface of the detector, which may be a photomultipliertube (PMT) (Hamamatsu). The surface of the reaction chamber may bereflective, in order to enhance the light collection properties of theelliptical shape. In some embodiments, the maximum diameter of thesurface of the PMT is limited to achieve a maximum signal to noise ratioof the output of the system. The diameter of the reaction chamber may bedesigned to approximately match the diameter of the PMT, whichinfluences the elliptical shape that can be achieved in a reactionchamber designed to hold a specific volume of fluids. Due to theconstrained elliptical shape, the reaction chamber surface color may bea partially diffusing white due to the additional light collection thatoccurs when light that would not otherwise be reflected directly to thePMT surface is partially diffused by the white surface and a fraction ofthis is directed toward the PMT surface. Alternatively, other surfacefinishes and materials such as a near-mirror finish aluminum, or atransparent material could be used if desired. Further, it is desirablefor the reaction chamber material to be minimally phosphorescent, inorder to prevent light emitted from the reaction chamber itself fromeclipsing any emitted light from the reagents and preventing detection.Although white polymeric materials such as acrylonitrile butadienestyrene or other such polymeric materials have been found to exhibit alow level of phosphorescence, the additional light collection providedby the combination of light reflection and diffusion has been found tobe a benefit to the signal to noise ratio of the light sensing circuitoutput.

In an exemplary embodiment, the testing subunit provides a system foruse in sample analysis. The system includes a biosensor reagent, whereinthe biosensor reagent includes living biological cells; a reservoircard, having a long loop portion and a short loop portion, wherein thereservoir card stores the biosensor reagent; and a test cartridge base,wherein the test cartridge base is configured to accept the reservoircard. The test cartridge base further includes: (i) a reaction chamberhaving a central axis, wherein the reaction chamber has the shape of arevolved half ellipse; and (ii) an inlet channel connected to thereaction chamber, wherein the inlet channel is positioned above thereaction chamber at an angle of 15-60 degrees above the horizontal,wherein the inlet channel is offset from the central axis of thereaction chamber, and wherein upon introducing a sample to be analyzedinto the test cartridge base through the inlet channel, the sample ishomogeneously mixed with the biosensor reagent while minimizing damageto the living biological cells.

In another exemplary embodiment, the testing subunit provides a systemfor rapidly detecting the presence of an analyte in a biological sample.This system includes a biosensor reagent including at least one antibodyspecific for a predetermined analyte and a bioluminescent agent, whereinthe at least one antibody is expressed on the surface of living,engineered lymphocytes and wherein the bioluminescent agent is expressedby the living, engineered lymphocytes, the biosensor reagent beingoperative to: (i) detect the presence of a specific analyte in a sampleto be tested, and (ii) emit a detectable light signal when the biosensorreagent reacts with the sample and detects the presence of the specificanalyte in the sample. A test cartridge is also included. The testcartridge further includes: (i) a reservoir card, wherein the reservoircard further includes the biosensor reagent; and (ii) a test cartridgebase, wherein the test cartridge base is configured to accept thereservoir card. The test cartridge base further includes: a) a reactionchamber having a central axis, wherein the reaction chamber has theshape of a revolved half ellipse; b) an inlet channel connected to thereaction chamber, wherein the inlet channel is positioned above thereaction chamber at an angle of 15-60 degrees above the horizontal, andwherein the inlet channel is offset from the central axis of thereaction chamber; and c) wherein upon introducing the sample into thetest cartridge base through the inlet channel, the sample ishomogeneously mixed with the biosensor reagent while minimizing damageto the living, engineered lymphocytes and minimizing any bubbling of themixed biosensor reagent and sample in the reaction chamber. A testingunit adapted to receive the test cartridge is also included. The testingunit including a sensor for detecting the detectable light signalemitted by the biosensor reagent upon reacting with the sample, thedetection of the emitted detectable light signal being indicative of thepresence of the analyte in the sample and, wherein detection of thespecific analyte in the sample occurs in real time.

EXAMPLE BIOASSAY 1 Instant Addition of Antibodies

In an exemplary embodiment of the bioassay of the present invention,wherein the detector molecule is a soluble antibody, the solubleantibody and sample to be tested are mixed together immediately priorintroduction of the biosensor cells to the test sample. In thisembodiment, charged biosensor cells are centrifuged and concentrated toabout 400,000 cells/180 μL (adequate for a single reaction) in thecharging medium. A 180 μL (about 400,000 cells) aliquot of the chargedbiosensor cells is then loaded into the long loop portion of thereservoir card. For a positive control, 30 μL of anti-CD3ε antibody inRPMI media is loaded into the short loop portion of the reservoir card.The reservoir card is then locked into the test cartridge base. A 2 μLvolume of an antibody (at 0.5 mg/mL) against the target pathogen, suchas anti-E. coli O111 (wherein the target pathogen is E. coli O111), ismixed with 28 μL of the sample to be tested in the cartridge mixingchamber. The test cartridge base is inserted into the testing device andthe charged biosensor cells are injected into the reaction chamber toinitiate the reaction. The resulting signal is recorded for 4 to 8minutes and at the end of the test period, the 30 μL of anti-CD3εantibody is injected from the short loop of the reservoir into reactionchamber as a positive control reaction that is recorded for 2 minutes.As an alternative positive control, 30 μL of 0.61 mM Digitonin can beused rather than anti-CD3ε antibody. A negative control test can beperformed using a predetermined pathogen that is not specific for theantibody being used.

EXAMPLE BIOASSAY2 Coating Biosensor Cells with Antibodies

In another exemplary embodiment of the bioassay of the presentinvention, wherein the detector molecule is a soluble antibody, thebiosensor cells are coated with the soluble antibody for a period oftime prior to mixing the sample to be tested with the biosensor cells.In this embodiment, charged biosensor cells are centrifuged andconcentrated to about 400,000 cells/180 μL (adequate for one reaction)in the charging medium. A 180 μL (about 400,000 cells) aliquot of thebiosensor cells is then mixed with a 2 μL volume of an antibody (at 0.5mg/mL) against the target pathogen, such as anti-E. coli O111 (whereinthe target pathogen is E. coli O111), in an Eppendorf tube. Thebiosensor cells mixed with the antibody are incubated at roomtemperature for 10 minutes and then loaded into the long loop portion ofthe reservoir card. For a positive control, 30 μL of anti-CD3ε antibodyin RPMI media is loaded into the short loop portion of the reservoircard. The reservoir card is then locked into the test cartridge base. A30 μL volume of the sample to be tested is added into the reactionchamber. The test cartridge base is inserted into the testing device andthe biosensor cells are injected into the mixing chamber to initiate thereaction. The resulting signal is recorded for 4 to 8 minutes and at theend of the test period, the 30 μL of anti-CD3ε antibody is injected fromthe short loop of the reservoir into reaction chamber as a positivecontrol reaction that is recorded for 2 minutes. As an alternativepositive control, 30 μL of 0.61 mM Digitonin can be used rather thananti-CD3ε antibody. A negative control test can be performed using apredetermined pathogen that is not specific for the antibody being used.

EXAMPLE BIOASSAY3 Coating Analyte with Antibodies

In another exemplary embodiment of the bioassay of the presentinvention, wherein the detector molecule is a soluble antibody, theanalyte (e.g., pathogenic bacteria) is coated with the soluble antibodyfor a period of time prior to mixing the sample to be tested with thebiosensor. In this embodiment, charged biosensor cells are centrifugedand concentrated to about 400,000 cells/180 μL (adequate for onereaction) in the charging medium. A 180 μL (about 400,000 cells) aliquotof the biosensor cells is loaded into the long loop portion of thereservoir card. For a positive control, 30 μL of anti-CD3ε antibody inRPMI media is loaded into the short loop portion of the reservoir card.The reservoir card is then locked into the cartridge base. A 2 μL volumeof an antibody (at 0.5 mg/mL) against the target pathogen, such asanti-E. coli O111 (wherein the target pathogen is E. coli O111), ismixed with 28 μL of the sample to be tested in an Eppendorf tube. Thesample is incubated at room temperature for 10 minutes then added intothe cartridge mixing chamber. The cartridge is inserted into the PMT andthe biosensor cells are injected into the mixing chamber to initiate thereaction. The resulting signal is recorded for 4 to 8 minutes and at theend of the test period, the 30 μL of anti-CD3ε antibody is injected fromthe short loop of the reservoir into reaction chamber as a positivecontrol reaction that is recorded for 2 minutes. As an alternativepositive control, 30 μL of 0.61 mM Digitonin can be used rather thananti-CD3ε antibody. A negative control test can be performed using apredetermined pathogen that is not specific for the antibody being used.

The exemplary bioassays described herein may include other additivesthat reduce background noise and enhance signal. Using anti-CD3εantibody as a positive control, the system has been demonstrated todetect fewer than 10 charged biosensor cells in a mixture of 50,000uncharged biosensor cells. The biosensor itself has been demonstrated todetect 230 CFU of bacteria in a sample of 30 μL. In the bioassaysdescribed above, a proprietary monoclonal antibody (1F11) against E.coli O111 bacteria was used to detect E. coli O111 bacteria with E. coliO157 being used as a negative control. E. coli O157 was demonstrated togive negative results, thereby proving the specificity of the system.Numerous commercially available antibodies may also be used with thedescribed bioassay. With regard to the proprietary monoclonal antibody(1F11), antibody analysis and selection of the monoclonal antibody wasaccomplished as described below.

Antibody production was determined by an ELISA performed in 96-wellmultiwell plates. Each well was coated with different LPS (E. coli O157,E. coli O127, E. coli O111, E. coli O26, Klebsiella pnmemoniae,Salmonella enlerioa and naive sera) or bacteria cells (E. coli O157, E.coli O111, E. coli 26 and E. coli DH5α). Hybridoma supernatant fromdifferent clones of mAb O157 or mAb O111 were added to the wells.Horseradish peroxidase-conjugated (HRP) goat anti-mouse IgG was used fordetection (Appendix III.A.3). The two hybridoma clones (1B10 and 6G1) ofE. coli O157 exclusively recognize LPS of E. coli O157 and E. coli O157.The nine hybridoma clones of E. coli O111 specifically recognize LPS ofE. coli O111 and E. coli O111. The clones from the highest opticaldensity (OD) reading were chosen for validation, which was accomplishedas described below.

The hybridoma cell pellets were collected and stored at −80° C. beforeRNA extraction. The extracted RNA was used as a template for reversetranscription to cDNA, followed by nested PCR amplification. Allpositive PCR products were cloned into TA cloning vectors and sent forsequencing. The variable regions of the light chain and the heavy chainwere determined after analysis of sequences. Four single chainantibodies (scFv) of O157 (1B10) (customized mAb produced by FSC) andATCC HB 10452, as well as two single chain antibodies of O111 producedby FSC (1F11 and 1F2) were recombinantly expressed and purified byImmobilized metal ion affinity chromatography (IMAC). The sequence ofscFv was constructed as the following order: pel B secretionsignal+amino acid Alanine+Histidine tag+amino acidsGlycine-Serine-Serine-Glycine+TEV cleavage site+amino acidsGlycine-Serine-Serine-Glycine+heavy chain variable region+Linker regionSerine-Alanine-Aspartic Acid-AsparticAcid-Alanine-lysine-lysine-AsparticAcid-Alanine-Alanine-Lysine-Lysine-Aspartic Acid-AsparticAcid-Alanine-Lysine-Lysine-Aspartic Acid-Aspartic Acid+light chainvariable region. The purified scFvs were tested using multi-well platescoated with LPS of O157 or O111.

The purpose of this study was to investigate the interactions ofmonoclonal antibody (mAb) to whole bacterial cells (E. coli O157 or E.coli O111), and to estimate the kinetic constant (KD) ofantibody-bacterial interaction. In these assays, goat anti-E. coli O157polyclonal antibody, goat anti-E. coli O111 polyclonal antibody, threemonoclonal antibodies (1022, 1024 and 1061) against E. coli O157, andone monoclonal antibody against E. coli O111 were used. A CM5 sensorchip and amine coupling kit were also used. All assays were performed ona Biacore X100 instrument. In the protocol, one polyclonal antibody(against a select bacteria) was immobilized onto a CM5 sensor chip. Theselect bacteria was then bound followed by injection of a monoclonalantibody against the same bacteria in a continuous buffer flow. Theinteraction was monitored in real time. The relative binding of theantibody to each bacterium was recorded in resonance units (RUs).Results of the BIAcore analysis of binding an E. coli O157 specificantibody (mAb FF754) to E. coli O157 and E. coli O111 indicated thatO157 mAb was specific for its target antigen.

While the present invention has been illustrated by the description ofexemplary embodiments thereof, and while the embodiments have beendescribed in certain detail, there is no intention to restrict or in anyway limit the scope of the appended claims to such detail. Additionaladvantages and modifications will readily appear to those skilled in theart. Therefore, the invention in its broader aspects is not limited toany of the specific details, representative devices and methods, and/orillustrative examples shown and described. Accordingly, departures maybe made from such details without departing from the spirit or scope ofthe general inventive concept.

What is claimed:
 1. A chimeric fusion protein having an amino acidsequence selected from the group consisting of SEQ ID NOs: 2, 4, 6, 6,10, 12, and
 18. 2. A chimeric fusion protein having an amino acidsequence selected from the group consisting of SEQ ID NOS: 14 and 16.